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Abstract

Obesity is a worldwide health problem due to its epidemic proportions and high risk for
other metabolic disorders, such type 2 diabetes, cardiovascular diseases and certain
cancers. It is generally accepted that a chronic low-grade inflammatory state is at the
pathogenic core of obesity. High-fat diet-induced obesity features of hyperleptinemia,
hyperinsulinemia,

fat

deposition,

glucose

intolerance,

central

and

peripheral

inflammation, as well as central and peripheral leptin resistance and hypothalamic leptin
signaling compromised. Obesity also features of the impairment of prefrontal cortex, and
impairment of leptin-induced regulation of brain-derived neurotrophic factor (BDNF)
expression and synaptogenesis, which has been considered to be associated with the
incidence of neuronal degenerative diseases, cognitive decline, and depression. Some
plant-derived triterpene saponins are anti-inflammatory and inhibit the NF-κB signaling.
Those triterpene saponins are potential therapeutic agents for the obesity-associated
inflammation to be determined. Natural extracted triterpene saponins, ginsenoside Rb1
and teasaponin, are used in this PhD research project. Ginsenoside Rb1, extracted from
Ginseng, has anti-inflammation effect and anti-obesity effect. However, it is unclear
whether it has the effect of anti-obesity-associated inflammation and whether it can
address the above listed features issue of obesity. Teasaponin is an active compound of
tea extract, has been demonstrated to ameliorate obesity, reduce inflammation and
improve central leptin sensitivity in obese mice in our previous study. Tea consumption
improves cognition and increases brain activation in the prefrontal cortex. However, little
is known on the ability of teasaponin on recognition memory and its effect on leptin
signaling in the prefrontal cortex of high-fat diet-induced obese mice.
The aim of Chapter 2 was to investigate the effects of ginsenoside Rb1 on treating
obesity, obesity-associated inflammation and central leptin resistance, as well as
hypothalamic leptin signaling. Results demonstrated that ginsenoside Rb1 treatment
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reduced food intake, prevented body weight gain and fat deposition, improved glucose
tolerance, as well as improved hyperleptinemia in high-fat diet-induced obese mice.
Furthermore,

ginsenoside Rb1 treatment

reduced obesity-associated

peripheral

inflammation and hypothalamic inflammation, indicating by the decrease expression of
TNFα, IL-6, IL-1β and pIKK. Ginsenoside Rb1 treatment also decreased the protein
expression of SOCS3 and PTP1B, the negative regulators of leptin signaling. The
reduced central inflammation and downregulation of SOCS3 and PTP1B by Rb1
treatment, contributed to the improvement of central leptin resistance and restore leptin
signaling in the mediobasal hypothalamus of obese mice treated with Rb1. Reduced
peripheral inflammation contributed to the improvement of glucose intolerance. Besides,
the increased expression of circulating PYY, and hypothalamic POMC upregulation and
AgRP downregulation extend the mechanism on suppressing food intake by Rb1.
The aim of chapter 3 was to examine the effects of ginsenosdie Rb1 on central leptin
effects on BDNF expression and synaptogenesis in the prefrontal cortex during obesity
via an in vivo and an in vitro model. Ginsenoside Rb1 chronic treatment improved central
leptin sensitivity, leptin-JAK2-STAT3 signaling and leptin-induced regulation of BDNF
expression in the prefrontal cortex of high-fat diet induced obese mice. In cultured
prefrontal cortical neurons, palmitic acid, the saturated fat, impaired leptin-induced
BDNF expression, reduced the immunoreactivity and mRNA expression of synaptic
proteins, and impaired leptin-induced neurite outgrowth and synaptogenesis. Importantly,
Rb1 significantly prevented these pernicious effects induced by palmitic acid. These
results indicate that Rb1 reverses central leptin resistance and improves leptin-BDNFneurite outgrowth and synaptogenesis in the prefrontal cortical neurons.
The aim of chapter 4 was to evaluate the effects of teasaponin on recognition memory
and leptin signaling in the prefrontal cortex of obese mice, and on leptin effects on
neurogenesis in the saturated fatty acid, palmitic acid, treated primary cortical neurons.
Oral teasaponin treatment significantly improved memory deficit in high-fat diet (HFD)
fed mice assessed by the novel object recognition test. Furthermore, teasaponin treatment
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(10mg/kg, intraperitoneal) for 21 days improved downstream leptin signaling (JAK2, and
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HFD fed mice. In the in
vitro study, teasaponin reversed the impairment caused by palmitic acid on the leptinmediated BDNF expression, leptin-mediated neurite outgrowth (MAP2 mRNA, neurite
branching and length), and synaptogenesis (PSD95 expression). These results indicate
teasaponin improves obesity associated recognition memory deficit and central leptin
effects on BDNF, neurite outgrowth and synaptogenesis in the prefrontal cortex.
In conclusion, this thesis demonstrated two natural triterpene saponins, ginsenoside Rb1
and teasaponin, as the potential therapeutic agents for obesity and obesity-associated
neuronal degenerative diseases, cognitive decline, and depression. Those therapeutic
effects benefit from the properties of these two triterpene saponin targeting on antiobesity-associated inflammation, positive regulation of central leptin signaling, and
reversal of central leptin resistance. Overall, both ginsenoside Rb1 and teasaponin
supplementation may be used to treat obesity, and prevent obesity-associated
neurodegeneration and improve cognitive function.
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CHAPTER ONE
1.1 Introduction
The prevalence of obesity is a worldwide health problem, which affects one third of the
world’s population (Hruby and Hu, 2015; Ng et al., 2014; Stevens et al., 2012) and
causes great economic burden (Hruby and Hu, 2015). It is an important risk factor for the
development of type 2 diabetes, cardiovascular disease, and certain cancer, as well as
depression, and neurodegenerative diseases(Hruby and Hu, 2015). Increasing evidence
indicated that a chronic low-grade inflammatory state during obesity is the core
pathogenic of obesity and type 2 diabetes (Cai et al., 2005; Lumeng and Saltiel, 2011).
The pro-inflammatory response includes elevated pro-inflammatory, such as tumor
necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 1 beta (IL-1β), and
activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
signaling pathway, including inhibitor kappa B alpha (IκBα) and IκB kinase (IKK)
(Osborn and Olefsky, 2012; Thaler et al., 2012). The activation of pro-inflammatory
cytokines and NF-κB signaling pathway induce insulin and leptin resistance in the
peripheral tissue and the central nervous system (Hayden and Ghosh, 2008; Zabolotny et
al., 2002; Zhang et al., 2008). Obesity-associated inflammation in the liver and white
adipose tissue leads glucose intolerance, insulin resistance and metabolic dysfunction
(Cai et al., 2005; Stanton et al., 2011b; Xu et al., 2003). Over-nutrition and obesity also
leads to hypothalamic inflammation, which results in the central leptin resistance, hepatic
insulin resistance, a reduction in thermogenesis, and cardiovascular disorders (Arruda et
al., 2011; Cai and Liu, 2011; Thaler et al., 2010; Thaler and Schwartz, 2010; Wisse and
Schwartz, 2009). Therefore, to treat obesity and metabolic syndrome, it is quite necessary
to block peripheral and central inflammation. Furthermore, obesity impairs prefrontal
cortex, which is a major regulatory center for cognitive function (Frith and Dolan, 1996;
Le et al., 2006). Obesity impairs leptin-induced regulation of BDNF expression, neurite
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outgrowth and synaptogenesis, which has been considered to be associated with the
incidence of neuronal degenerative diseases, cognitive decline, and depression (Gupta et
al., 2013; Vanevski and Xu, 2013; Zuccato and Cattaneo, 2009). Hence, it is essential to
attenuate the obesity-associated impairment of cortical leptin-BDNF, neurite outgrowth
and synaptogenesis to prevent the risk of development obesity-associated metabolic
disorder and neurodegeneration.
Studies showed that some triterpene saponins are naturally derived inhibitors of NFκB
signaling and have anti-inflammatory potential (Salminen et al., 2008b).Triterpene
saponin ginsenoside Rb1, one of the active compounds extracted from ginseng, has been
reported to have anti-inflammation effect, anti-obesity effect and neuroprotective effect
(Kim et al., 2014; Li et al., 2011b; Lin et al., 2013; Liu et al., 2011a; Nam et al., 2013;
Wang et al., 2008; Xiong et al., 2010; Xue et al., 2006; Yuan et al., 2007). Reports also
indicated, tea and tea extract (including teasaponin) has anti-inflammatory effect (Park et
al., 2011; Ren et al., 2018). However, it is unknown whether Rb1 can improve obesityassociated inflammation and leptin resistance, and also unknown the effects of Rb1 on
leptin-BDNF, neurite outgrowth. It is also unclear the effects of teasaponin on obesityassociated leptin resistance, leptin-BDNF-neurite outgrowth and neurogenesis, as well as
obesity-associated recognition impairment. The present PhD series studies were designed
to investigate the chronic treatment effects of Rb1 on body weight change, energy intake,
obesity-associated peripheral and hypothalamic inflammation, glucose intolerance and
central leptin resistance, cortical leptin sensitivity and synaptogenesis of high-fat dietinduced obese mice, as well as effects of teasaponin on obesity-linked recognition
impairment and cortical leptin sensitivity. These series PhD studies will provide new
potential anti-obesity therapeutic agents that modulate obesity-associated inflammation,
central leptin sensitivity and prevent obesity-associated neurodegeneration.
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1.2 Literature Review
1.2.1 Obesity
The prevalence of overweight and obesity has been reached the worldwide epidemic
proportion. In 2013, the proportion of overweight and obese adults increased to 36.9% in
men, and 38% in women worldwide; the proportion of overweight and obese children and
adolescents in developed countries increased to 23.8% in boys and 22.6% in girls (Ng et
al., 2014). As the established health risks and the substantial globally increase in
prevalence, obesity has become a major global health challenge and a heavy burden on
financial of health care systems worldwide. Globally, it is estimated that overweight and
obesity caused 3.4 million deaths, 3.9% of the years of life lost and 3.8% of disabilityadjusted life-years in 2010 (Ng et al., 2014). In Australia, about 27% of children and
adolescents and 63% of adults were overweight or obese in 2014-2015(AIHW, 2017). In
Australia in 2011, 7% of the total health burden was attributed to overweight and obesity,
63% of which was fatal burden. It is estimated that obesity has cost $8.6 billion of the
Australian economy in 2011-2012(AIHW, 2017). Also, obesity leads to higher likelihood
of chronic diseases such as cardiovascular disease, type 2 Diabetes Mellitus, stoke,
osteoarthritis, respiratory, sleep problems, hypertension and certain types of cancers
(Dakin et al., 2004; Daling et al., 2001; Huang and Chen, 2009). The issue of obesity will
lead to both increased mortality and morbidity (Frezza, 2004; Kojima et al., 2009).
Therefore, due to the medical complication and the associated tremendous economic
consequences, the alarming growth rate undeniably makes obesity an urgent and critical
issue to be addressed (Devlin et al., 2000; Marx, 2003; Wisse et al., 2007).
Obesity results from a sustained energy imbalance—when the energy intake is greater
than energy expenditure. It can be attributed by both genetic predisposition and lifestyle
factors such as overconsumption of high energy density diet, sedentary lifestyles and
reduction in physical activity (Brown et al., 2009; Challis et al., 2003; Hill and Peters,
1998; Perusse and Bouchard, 2000). Epidemiological studies have shown that the
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consumption of high-fat diets is positively associated with body weight gain and obesity
in human population (Bray and Popkin, 1998; Koegler et al., 1999; Macdiarmid et al.,
1996; Smyth and Heron, 2006).

1.2.2 Dietary fat consumption and high-fat diet-induced obese mouse model
Excessive energy intake by overconsumption of diet that rich in saturated fat contributes
to energy imbalance and weight gain, leading to overweight and obesity (Brooks et al.,
2013; Hill et al., 2000). In a human study, a diet with >35% energy as fat, is classified as
a high-fat diet (HFD), and promotes body weight gain both in men and women (Donnelly
et al., 2008). Strong evidence suggests greater intake of energy-enrich diet is associated
with bigger body fat mass among children and higher body weight among adults (AIHW,
2017). Therefore, to address the obesity issue, high-fat diet is used to establish high-fat
diet-induced obesity (DIO) animal models to mimic the most common cause of obesity in
humans.
In a DIO mouse model, the development of chronic high-fat diet-induced obesity is a
progressive process varying in energy intake, body weight gain and leptin sensitivities at
different stages. It can be divided into Early Response (Stage1-DIO, < 5 wks), Middle
Regulatory (Stage 2-DIO, from 5 to 15 wks), and Late Failure (Stage 3-DIO, > 15 wks)
Stages (Lin et al., 2000b). It can be summarized as in the early stage the body responds to
high-fat diet, while in the middle stage the body tries to prevent excessive fat stores by
activation of its regulatory system, and finally chronic consumption of high-fat diet
eventually fails the regulatory system and results in obesity (Table 1). In parallel with
these whole-body measures of energy balance, our lab have further demonstrated as well
the progressive dysregulation of leptin secretion, peripheral and then central leptin
insensitivity,

central

leptin

receptor

gene

expression,

and

the

downstream

neurotransmitter expressions (Table 1).
The impairment of the potential molecular pathways behind the central nerves system,
which may links to the dysregulation of food intake and body weight, may mainly
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attribute to the development of DIO and related leptin insensitivities. This study used the
DIO mouse model to address the metabolic disorders.
Table1.1. Characteristics of three stages of diet-induced obesity
Early stage

Middle stage

Late stage

(week 1)

(week 8)

(week 19)

Body weight

ND

↑11%

↑30%

(Lin et al., 2000b)

Energy intake

↑Slightly (ND)

↓16%

↑15%

(Lin et al., 2000a)

RVB

ND

↑45%

↑84%

(Lin et al., 2000a)
(Lin et al., 2000b)

Leptin

2ug/g i.p.

Yes

No

No

sensitivity

0.1ug/g icv

Yes

Yes

No

ND

↑

↑

Arc

LR mRNA

Reference

(Huang

et

al.,

2003a; Huang et
al., 2003b; Lin et
al., 2000a)
POMC mRNA

ND or ↑

ND

↓

(2 weeks)

(Huang

et

al.,

2003a; Huang et
al., 2003b; Lin et
al.,

2000a;

Ziotopoulou et al.,
2000)
NPY mRNA

ND or ↓

↓

↑

(2days)

(Huang

et

al.,

2003a; Huang et
al., 2003b; Lin et
al.,

2000a;

Ziotopoulou et al.,
2000)
AgRP

↓(2days)

↓

↓

(Huang

et

al.,

2003a; Huang et
al.,

2003b;

Ziotopoulou et al.,
2000)
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conclusion

Response

to

Compensatory

Failure

high-energy diet

attempts to limit

regulatory

with

excessive fat stores

systems

by

ensuing rapid fat

slight

hyperphagia

activation

of

regulatory system

of

with

accumulation

ND: no statistical difference; RVB: ratio of visceral fat (mg)/body weight (g); LR: leptin
receptor;

POMC: proopiomelanocortin; NPY: neuropeptide Y; AgRP: agouti related-protein

1.2.3 Leptin signaling and central leptin resistance
1.2.3.1 Leptin and leptin signaling
Leptin, a 16 kDa peptide hormone consisting of 167 amino acid residues, is produced by
adipocytes in proportion to fat stores. Accumulating evidences show that leptin acts on
brain to regulate energy balance via activating leptin receptor and related signaling
(Bjorbaek and Kahn, 2004; Fruhbeck, 2006). Leptin receptors, members of the class I
cytokine receptor family, exert its function through JAKs (Janus kinases) and STATs
(signal transducers and activators of transcription). Leptin receptor b, the full-length
isoform, is considered to be the functional receptor to activate the JAK/STAT signal
transduction pathway (Fruhbeck, 2006). It is clear that leptin receptor b is highly
expressed in multi-regions of hypothalamus, especially in the arcuate nucleus of
the hypothalamus (Arc) area (Bjorbaek and Kahn, 2004). The ARC region contains two
key populations of neurons, NPY and POMC neurons, which produce orexigenic
peptides and anorectic peptides, respectively (Cone, 2005). Leptin has been reported to
modulate the activity of both neurons, inducing the inhibition of NPY/AgRP mRNA
expression and the elevation of POMC mRNA expression (Enriori et al., 2006). In
addition, leptin activates leptin receptor b signaling in hypothalamus, including
JAK2/STAT3 and insulin receptor substrate/ phosphoinositide 3-kinase/protein kinase B
(IRS/PI3K/Akt), to regulate the feeding behavior (Hill et al., 2008; Sahu, 2004; Wauman
and Tavernier, 2011). Additionally, AMP-activated protein kinase (AMPK), fuel-sensing
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signaling has been suggested to involve in the regulation of leptin’s anorectic effect
(Blanco Martinez de Morentin et al., 2011; Gao et al., 2007; Morris and Rui, 2009).
Leptin receptor is also distributed in other regions of the brain, such as hippocampus and
prefrontal cortex (Ates et al., 2014). Recently, leptin-STAT3 has been reported to be
involved in the neuroprotection of cerebral ischemia via promoting neuronal survival in
vitro and in vivo (Amantea et al., 2011; Tang, 2008). Leptin signaling in the
hypothalamic and prefrontal cortex in obese were investigated in this PhD study.

1.2.3.2 Central leptin resistance and its underlying mechanism
It is well recognized that adequate circulating leptin provides a signal of energy stores to
central nervous system (CNS), enable the brain to adjust energy balance via suppressing
food intake and increasing the energy expenditure (Bates and Myers, 2003; Friedman and
Halaas, 1998). Conversely, lack of leptin signaling, such as attributing to mutation of
leptin (ob/ob mice) or leptin receptor (db/db mice) in rodents or human, leads to
hyperphagia and suppression of energy expenditure accompanied by increased expression
and secretion of orexigenic peptides (NPY and AgRP) (Ahima et al., 1996; Bates and
Myers, 2003; Lord et al., 1998). However, most obese humans and rodents do not have
lower circulating leptin. In fact, they usually have extremely high level of plasma leptin,
which still fails to reduce food intake and body weight and fails to increase energy
expenditure, showing the resistance to leptin effect.
The definition of leptin resistance is characterized by the failure of elevated circulating
leptin to suppress feeding and weight gain which in turn exacerbates obesity in general
(Enriori et al., 2006; Myers et al., 2008b). Recently researches produced a high-fat dietinduced obesity (DIO) model in several strains of rodents focusing on the issue of leptin
resistance (Hariri and Thibault, 2010; Howard et al., 2004; Judge et al., 2008; Levin and
Dunn-Meynell, 2002; Lin et al., 2000b; Metlakunta et al., 2008). The development of
high-fat diet-induced obesity and leptin resistance in C57BL/6J mice can be divided into
3 stages: early stage, middle stage and late stage. In the early stage, mice on HFD gain
Yizhen Wu

7

weight and remain response to peripheral leptin injection. In the middle stage, mice
elevate plasma leptin and fails to response to peripheral leptin but still sensitive to central
leptin administration. Finally, in the late stage, DIO mice with highly increasing body
adiposity and extreme high level of plasma leptin show central leptin resistance, failing to
suppress food intake and body weight in response to icv leptin administration (Lin et al.,
2000b).
Interestingly, Protein Tyrosine Phosphatase 1B (PTP1B), a cellular protein, has been shown
to implicate in the regulation of cellular leptin signaling. PTP1B dephosphorylates JAK2,
the initial tyrosine kinase mediating leptin signaling. Neuronal PTP1B knockout mice
have reduced body weight, food intake and enhanced leptin sensitivity (Bence et al.,
2006). Furthermore hypothalamic PTP1B is increased during HFD-induced leptin
resistance (White et al., 2009). The i.p. injection of PTP1B inhibitor Trodusquemine
(MSI-1436) decreased food intake and body weight in diet-induced obese mice (Lantz et
al., 2010). These results suggest PTP1B plays an important role in central leptin
insensitivity (Cheng et al., 2002; Myers et al., 2008b; Sahu, 2004).
Additionally, low-grade pro-inflammatory is at the pathogenic core of obesity. The
activation of pro-inflammatory cytokines and NF-κB signaling pathway mediate the
transcription of the suppressor of cytokine signaling 3 (SOCS3) and PTP1B, which will
induce insulin and leptin resistance in peripheral tissue and the central nervous system.
To alleviate the central leptin resistance, study 1 was carried out to investigate the effect
of chronic ginsenoside Rb1 treatment. Study 2 and study 3 were addressing leptin
resistance issue in the prefrontal cortex caused by the saturated fat.

1.2.4 Obesity-associated inflammation and its detrimental effects on leptin
resistance and cognitive decline
Chronic low-grade pro-inflammatory state is at the pathogenic core of obesity and type 2
diabetes (Cai et al., 2005; Lumeng and Saltiel, 2011). This inflammatory response
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includes elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor
alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), and activation of the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling
pathway, including inhibitor kappa B alpha (IκBα) and IκB kinase (IKK) (Osborn and
Olefsky, 2012; Thaler et al., 2012). The activation of pro-inflammatory cytokines and
NF-κB signaling pathway mediate the transcription of the suppressor of cytokine
signaling 3 (SOCS3) and protein-tyrosine phosphatase 1B (PTP1B), negative regulators
of insulin and leptin signaling, which induce insulin and leptin resistance in peripheral
tissues and the central nervous system (Hayden and Ghosh, 2008; Zabolotny et al., 2002;
Zhang et al., 2008). Obesity associated inflammation in white adipose tissue and the liver
leads to glucose intolerance, insulin resistance and metabolic dysfunction (Cai et al.,
2005; Stanton et al., 2011b; Xu et al., 2003). Over-nutrition and obesity also leads to
hypothalamic inflammation and stimulation of local proinflammatory NF-κB signaling,
resulting in the dysfunction of hypothalamic neurons (Thaler et al., 2012; Zhang et al.,
2008). Furthermore, recent studies have shown that induction of inflammation in the
hypothalamus results in experimental obesity, resistance to the anorexigenic hormone
leptin, peripheral insulin resistance and defective regulation of food intake and energy
expenditure (Arruda et al., 2011; Calegari et al., 2011; Milanski et al., 2012).
Neuroinflammation in obesity could contribute to cognitive decline and dementia. Proinflammatory cytokines, such as IL-6 and IL-1β have been reported to disrupt neural
circuits involved in cognition and memory (Gemma and Bickford, 2007; Jankowsky and
Patterson, 1999; Nguyen et al., 2014). For instance, juvenile HFD intake promotes LPSstimulated IL-1β and TNFα expression in the hippocampus, which is likely to be
contributed to a selective impairment of consolidation that impaired long-term spatial
memory but not short-term memory (Boitard et al., 2014a). Besides, in children, intake of
saturated fatty acids impairs both relational and item memory (Nguyen et al.,
2014). Obesity-associated inflammation in hypothalamus and hippocampus has been
reported (Arruda et al., 2011; Boitard et al., 2014a; Cai and Liu, 2011). While at this
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stage the prefrontal cortex is to be investigated. As obesity-associated inflammation
deleterious leptin resistance and neurodegeneration, it is valuable to pursuit therapeutic
agents that have anti-obesity, anti-inflammation and alleviating neurodegenerative
effects.

1.2.5 BDNF and neurite outgrowth and synaptogenesis regulation by leptin
Brain-derived neurotrophic factor (BDNF) plays an important role in neurite outgrowth
(ie, elongation and branching), synaptic plasticity, synaptogenesis and the regulation of
energy balance (Noble et al., 2011; Yu et al., 2009), through the activation of its receptor
tropomyosin-related kinase B (TrkB). Aberrant BDNF/TrkB signaling is associated with
obesity, cognitive impairment, and other neurodegenerative diseases (Gupta et al., 2013;
Vanevski and Xu, 2013). Moreover, the BDNF gene mutation is associated with
increasing early-onset obesity and cognitive impairment in BDNF-haploinsufficient
patients (Gray et al., 2006). The BDNF protein level in the prefrontal cortex is decreased
in rodents fed a chronic high-fat (HF) diet (Kanoski et al., 2007b). Furthermore, leptin,
secreted from adipocytes, is a key regulator of BDNF expression in the hypothalamus
(Liao et al., 2012) and brain stem (Bariohay et al., 2005a), promoting negative energy
balance. Leptin increases hippocampic BDNF in normal mice, but not in diet-induced
obese (DIO) mice, which exhibit depressive behaviour (Yamada et al., 2011), suggesting
central leptin resistance in the obese mice. Thus the impairment of leptin-regulated
BDNF in the prefrontal cortex by saturated fat may play an important role in central
nervous system dysfunction in obese subjects. Improving leptin-regulated BDNF is
imperative to improving obesity-associated brain dysfunction, including cognitive
impairment.
Leptin involves in the regulation of the cellular events including neurogenesis, axon
growth, and synaptogenesis (Bouret, 2010). Leptin has been shown to regulate
neurogenesis, such as increasing axonal growth cone size in cortical neurons (Valerio et
al., 2006). Recently, leptin-STAT3 has been reported to be involved in the
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neuroprotection of cerebral ischemia via promoting neuronal survival in vitro and in vivo
(Amantea et al., 2011; Tang, 2008). It is known that leptin signaling molecules, JAK2
and STAT3, distribute around the postsynaptic sites in the cerebral cortex (Murata et al.,
2000). An immunocytochemistry study also shows BDNF and TrkB lie in the
postsynaptic densities in the cerebral cortex of adult rats (Aoki et al., 2000). These
findings suggest that leptin-JAK2-STAT3 signaling and BDNF/TrkB might regulate
synaptogenesis and synaptic plasticity in the prefrontal cortex. Study 2 and study 3 focus
on the hypothesis that leptin will regulate BDNF, neuritegrowth and synaptogenesis in
the prefrontal cortex.

1.2.6

Obesity-associated

impairment

of

prefrontal

cortex

and

neurodegeneration
Apart from hippocampus, the prefrontal cortex is another important brain region which
regulates cognition. Impairment in the prefrontal cortex has been identified in obesity,
mood disorders and neurodegenerative diseases. For example, obese women have a lower
activation in the prefrontal cortex in response to a meal than lean women examined by
positron emission tomography (Le et al., 2007). The abnormal structure and dysfunction
in the prefrontal cortex is associated with depression and anxiety-like behaviours and
Alzheimer’s disease (Drevets et al., 2008).Cross-sectional study on obesity and brain
structure showed that higher levels of BMI were associated with lower global brain
volume, and

dorsolateral prefrontal cortex (DLPFC) in obese individuals was

preferentially vulnerable to atrophy (Bischof and Park, 2015; Brooks et al., 2013; Ward et
al., 2005).
Obesity is associated with the neurodegenerative diseases. It is reported that obese
rodents induced by a high-saturated fat diet have cognitive impairment, depressive
behaviour, and central leptin resistance (Farr et al., 2008; Kanoski and Davidson, 2011;
Yamada et al., 2011). Alzheimer’s disease has been linked to a HFD and neuronal leptin
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resistance (Bonda et al., 2014; Hanson et al., 2013). Overweight/obesity individuals at
varying degrees of risk for bipolar disorder exhibit greater cognitive impairment
(McIntyre et al., 2017). A cross-sectional study revealed early cognitive decline in the
obese participants, indicated by their normal but significantly lower performance on
attention and more impulsive compared to the normal weight participants (Cook et al.,
2017). Since obesity increase the neurodegeneration, the research on potential therapeutic
agents to treat obesity-associated neurodegenerative disorders is quite essential.

1.2.7 Triterpene saponins
Plant triterpene saponins, biologically, are considered defensive compounds against
pathogenic microbes and herbivores. These saponins also have beneficial properties for
humans. For instance, Panax plant, well-known traditional herbal medicines, contains
saponins (including ginsenosides) with various pharmacological effects (Sawai and Saito,
2011; Shibata, 2001). Triterpene saponins are groups of pant secondary metabolites with
structurally composed of a lipid soluble aglycone and a water soluble sugar residues
(Abid Ali Khan et al., 2012). The amphiphilic nature of the triterpene saponins suggests
that they intercalate into the cell membrane (Abid Ali Khan et al., 2012) to mediate the
cellular events. Some plant-derived triterpene saponins are anti-inflammatory and inhibit
the NF-κB signaling pathway (Salminen et al., 2008b).
In this study, triterpene saponins ginsenoside Rb1 and teasaponin, derived from ginseng
and tea respectively, were used on the animal models to treat obesity-associated
metabolic dysfunctions, such as leptin resistance.

1.2.7.1 Ginsenoside Rb1
Ginseng, a traditional herbal medicine, is reported to be adaptogen that enhances body
stability against physical loads, and is also suggested to improve cognitive function (Heo
et al., 2011). Ginsenosides, the mainly active constituents that are found in extracts of
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varies species of ginseng, attribute to the pharmacological properties of ginseng (Attele et
al., 1999b). Ginsenoside Rb1 (Rb1) is one of the major bioactive components of ginseng
saponins. It has been well chemically characterized, which has the structure of a
tetracyclic triterpenoid with a molecular weight of 1109.26 and a molecular formula of
C54H92O23 (Figure 1.1) (Cho et al., 2004). Rb1 has an amphiphilic nature that enables it to
intercalate the plasma membrane, affect membrane function, and elicit a cellular response
(Abid Ali Khan et al., 2012). This compound inhibits inflammation in in vitro and in vivo
models, including anti-inflammatory effects on aortic smooth muscle exposed to TNF-α
(Li et al., 2011a), the colon of mice with colitis (Joh et al., 2011), and brain tissue in an
cerebral ischemia animal model (Zhu et al., 2012). Both human and animal studies have
demonstrated various physiological effects of Ginsenosides in increasing satiety and
improving glucose metabolism. Recent studies suggested that ginsenosides has
anorexigenic effect and anti-obesity effect (Etou et al., 1988; Shang et al., 2008; Xiong et
al., 2010). Rats acute intraperitoneal administrated of Rb1 (10mg/kg) significantly
decreased food intake during 4-10 hours after treatment. Chronic treatment of Rb1 (ip)
for 4 weeks significantly reduced food intake, body weight, plasma leptin, fasting glucose
and hypothalamic NPY mRNA expression level in DIO rats after 13 weeks’ HFD
feeding. Furthermore Rb1 (10µmol/L) treated on primary hypothalamic neurons activated
Akt, leptin signaling, peaking at 3h after treatment (Xiong et al., 2010). Ginseng berry
extract has been used to treat leptin receptor deficient obese mice (ob/ob), showing
decreased food intake and body weight, reduced hyperglycemia and improved glucose
intolerance (Attele et al., 2002). Similarly, the saponins of ginseng can inhibit food
intake, decrease body weight and blood glucose and improve insulin sensitivity in dietinduced obese rats and mice (Kim et al., 2005; Lin et al., 2013). Furthermore, oral
administration of ginseng can increase insulin sensitivity and improve glucose intolerance
in patients suffering Type 2 diabetes (Vuksan et al., 2008).
Recent animal and cell models show that Rb1 has neuroprotective (Gao et al., 2010; Zhu
et al., 2012) and anti-obesity effects (Xiong et al., 2010). For example, Rb1 increases
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BDNF expression in rats with cerebral ischemia (Gao et al., 2010). Clinical data shows
that ginseng treatment for 24 weeks improves cognitive function for up to 2 years in
patients with Alzheimer’s disease (Heo et al., 2011).
However, it is unknown whether Rb1 can improve obesity-associated inflammation,
central leptin resistance and obesity-associated impairment of neurite outgrowth and
synaptogenesis. Study 1 and 2 focused on those issues.

Figure 1.1 Chemical structure of ginsenoside Rb1. Adapted from (Cho et al., 2004)

1.2.7.2 Teasaponin
Tea has been widely used as a healthy drink worldwide from ancient times. The earliest
use of tea for medicinal purposes occurred in China, in roughly 2700 BC during the time
of Emperor Shen Nung (Weisburger, 1997). During that time, it was believed to have
health promoting properties, and was frequently used as a fluid supply for patients with
infectious diseases. Evidence from clinical and animal studies show that tea has antiobesity effects (Beresniak et al., 2012a; Wolfram et al., 2006), prevent abnormal glucose
and lipid metabolism (Beresniak et al., 2012a; Park et al., 2011), anti-inflammation
(Henning, 2012; Park et al., 2012) and improves cognitive function (Kuriyama et al.,
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2006; Ng et al., 2008). Treatment with 1 % tea extract in diet for 6 weeks decreased body
weight, adipose mass, hepatic TNF-α protein and adipose TNF-α mRNA, and attenuated
hepatic steatosis in genetically obese (ob/ob) mice (Park et al., 2011). Supplementation of
HFD with tea extract significantly reduced HFD induced p-IκBα and NF-κB activity in
liver and adipose tissue (Park et al., 2012). Increased consumption of green tea was
associated with a lower prevalence of cognitive impairment in a cross-sectional study in
1003 Japanese (Kuriyama et al., 2006), and longitudinal analysis of data from 1438
Chinese subjects (Ng et al., 2008). Phenolics and saponin are the two major active
components extracted from tea. Phenolics in tea have been widely investigated in
previous studies, while teasaponin has received little attention. Teasaponins, an important
bioactive ingredient naturally extracted from varies of teas, can reduce the elevation of
the rat plasma triacylglycerol level caused by an oral administration of a lipid emulsion
(Han et al., 2005). Study showed that oral 0.5% teasaponin with HFD for 11 weeks
significantly decreased body weight, parametrial adipose tissue weight and reduced the
diameters of adipocyte (Han et al., 2001). Chemically teasaponin belongs to the
oleanane-type pentacyclic triterpene saponins, whose amphiphilic nature enables them to
intercalate into the cell membrane and interact with cell membrane molecules to regulate
downstream signaling cascades (Abid et al., 2012; Attele et al., 1999a). Recently
teasaponin (10mg/kg ip injection) showed significant anti-inflammatory properties, by
inhibiting paw oedema induced by carrangeenan in rats (Sur et al., 2001). In the current
study, we investigated whether teasaponin could improve central inflammation and leptin
sensitivity in the hypothalamus and prefrontal cortex of obese mice. We further
investigated the effect of teasaponin on neurite outgrowth in cultured primary prefrontal
cortical neurons in response to leptin and the saturated fatty acid, palmitic acid.
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1.3 Aims and Hypotheses
1.3.1 Aims
1.3.1.1 General Aim
To evaluate the effects of triterpene saponins (Ginsenoside Rb1 or Teasaponin) on highfat diet-induced obesity, obesity-associated inflammation, hypothalamic leptin signaling,
central leptin sensitivity, and cortical leptin signaling, as well as leptin-induced of BDNF
expression and neurogenesis in the prefrontal cortex during obesity via an in vivo and an
in vitro model.

1.3.1.2 Specific Aims
The specific aims of this research were to:
1. Investigate the effect of ginsenoside Rb1 on high-fat diet-induced obesity, glucose
intolerance, obesity-associated inflammation, central leptin resistance and central
leptin signaling in the high-fat diet-induced obese mouse model.
2. Examine the effects of ginsenosdie Rb1 on central leptin effects on BDNF expression
and synaptogenesis in the prefrontal cortex during obesity via an in vivo and an in
vitro model.
3. Evaluate the effect of teasaponin on obesity, obesity-associated central inflammation
and leptin sensitivity in the hypothalamus and prefrontal cortex of obese mice, and on
leptin effects on BDNF and neurite outgrowth in cultured primary prefrontal cortical
neurons in response to leptin and the saturated fatty acid, palmitic acid.

1.3.2 Hypotheses
1. Ginsenoside Rb1 will ameliorate high-fat diet-induced obesity, obesity-associated
inflammation, glucose intolerance, and restore central leptin sensitivity, as well as central
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leptin signaling in the high-fat diet-induced obesity.
2. Ginsenoside Rb1 will improve central leptin effects on BDNF expression and
synaptogenesis in the prefrontal cortex during obesity in in vivo and in vitro.
3. Teasaponin will ameliorate obesity, central inflammation; improve memory and leptin
sensitivity in the hypothalamus and prefrontal cortex of obese mice; and to improve
leptin effects on BDNF and neurite outgrowth in the palmitic acid pre-treated cortical
neurons.

1.3.3 Significance
Obesity has been reached epidemic proportions and is an important risk factor for the
development of type 2 diabetes, cardiovascular disease and cancer. It is generally
accepted that a large component of obesity-associated pathophysiology may stem from a
low-grade pro-inflammation that occurs during obesity. The pro-inflammatory response
includes elevated pro-inflammatory cytokines and activation of NFκB signaling pathway.
The activation of pro-inflammatory cytokines and NFκB signaling pathway induce
insulin and leptin resistance in the peripheral tissue and the central nervous system.
Obesity-associated inflammation in white adipose tissue and the liver leads glucose
intolerance, insulin resistance and metabolic dysfunction. Over-nutrition and obesity also
leads to hypothalamic inflammation. Hypothalamic inflammation results in the central
leptin resistance, hepatic insulin resistance, a reduction in thermogenesis, and
cardiovascular disorders. Furthermore, obesity impairs prefrontal cortex, which is a major
regulatory center for cognitive function. Obesity impairs leptin-induced regulation of
BDNF expression, neurite outgrowth and synaptogenesis, which has been considered to
be associated with the incidence of neuronal degenerative diseases, cognitive decline, and
depression. Therefore, strategies to attenuate the obesity-associated peripheral and
hypothalamic inflammation, central leptin resistance and impairment of cortical leptinBDNF, neurite outgrowth and synaptogenesis may help to prevent the risk of
development obesity-associated metabolic disorder and neurodegeneration.
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Studies showed that some triterpene saponins are naturally derived inhibitors of NFκB
signaling and have anti-inflammatory potential. Ginsenoside Rb1, one of the triterpene
saponin, has been reported to have anti-inflammation effect, anti-obesity effect and
neuroprotective effect. Reports also indicated, tea and tea extract (including teasaponin)
has anti-inflammatory effect. However, it is unknown whether Rb1 can improve obesityassociated inflammation and leptin resistance, and also unknown the effects of Rb1 on
leptin-BDNF, neurite outgrowth. It is also unclear the effects of teasaponin on obesityassociated hypothalamic inflammation, obesity-associated leptin resistance, leptinmediated BDNF expression and leptin-mediated neurite outgrowth, as well as obesityassociated recognition impairment. This research will explore chronic treatment effects of
Rb1 on obesity-associated inflammation and central leptin resistance, cortical leptin
sensitivity and synaptogenesis, as well as effects of teasaponin on obesity-associated
hypothalamic inflammation, obesity-linked recognition impairment, and hypothalamic
and cortical leptin sensitivity. This research will provide new potential anti-obesity
therapeutic agents that will modulate obesity-associated inflammation, central leptin
sensitivity and prevent obesity-associated neurodegeneration.

1.4 General Methods and Materials
1.4.1 Ethics statement
All procedures of animal studies included in this study were approved by the Animal
Ethics Committee of the University of Wollongong, NSW, Australia (Application
Approval#: AE10/08), and complied with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes, which is in accordance with the International
Guiding Principles for Biomedical Research Involving Animals. All efforts have been
made to minimize animal numbers, animal stress and prevent suffering.

1.4.2 Animals care and Drug Treatments
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C57Bl/6 male mice were obtained from the Animal Resources Centre (Perth, Western
Australia) and housed in environmentally controlled conditions (temperature 22 °C, 12
hour light/dark cycle). All animals were fed a lab chow (LC) diet (5% fat, Vella Stock
Feeds, Doonside, NSW, Australia) ad libitum to acclimatize for one week. Throughout
the study, LC was served as the low fat control diet and was provided a d libitum except
where noted.

1.4.2.1 Acute Ginsenoside Rb1 treatment for central leptin sensitivity test
In study 1 (chapter 2), after acclimatization, mice were fed a HFD for 8 weeks to generate
the moderate obesity mice (The HFD contained 40% of energy as fat, SF11-095,
Specialty Feeds, Western Australia). Then an intracerebroventricular cannula was
implanted (detailed in section 1.3.4). After 5 days of recovery, the obese mice were then
acute treated with Rb1 by intraperitoneal injected with Rb1 for two consecutive days.
Central leptin sensitivity was then carried out on the mice (detailed in section 1.4.4). The
dosage of Rb1 was 14 mg/kg, based on a Rb1 dose (10mg/kg) described previously in
rats (Xiong et al., 2010), and using a body surface area ratio of 0.14 from rat to mouse
(Paget and Barnes, 1964). Rb1 purified by high-performance liquid chromatography
(HPLC) to ≥98% was purchased from Jilin University in China.

1.4.2.2 Chronic Ginsenoside Rb1 treatment
In study 1 (chapter 2) and study 2 (chapter 3), after acclimatization, mice were then fed a
HFD for 16 weeks to induce the late stage of obesity. After 16 weeks of HFD, obese mice
were randomized into two groups (n=16 per group) and chronic treated with either daily
intraperitoneal (ip) injections of Rb1 (14 mg/kg) or vehicle (saline) for 21 days. This
study also included a parallel control group of age-matched mice fed a LC diet. During
Rb1 treatment the animal’s food intake and body weight were recorded daily. On day 18
of Rb1 treatment, an intraperitoneal glucose tolerance test was performed (detailed in
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section 1.4.3). On day 21 of Rb1 treatment, an intracerebroventricular cannula was
implanted and central leptin sensitivity test was performed (detailed in section 1.4.4).
Figure 1.2 was the flow chart of triterpene saponin chronic treatment on experimental
obese mice.
This part of chronic Rb1 treatment was both included in chapter 2 and chapter 3.

Figure 1.2 Flow chart of triterpene saponin chronic treatment on experimental obese mice.
Wks: weeks; D: day; GTT: glucose tolerance test; BW: body weight; FI: food intake; h: hour (s);
icv: intracerebroventricular.

1.4.2.3 Chronic Teasaponin treatment
In study 3 (chapter 4), mice were placed on the HFD for 16 weeks. The animals were
then randomized into two groups, and administered either teasaponin (10 mg/kg) or
vehicle (saline) i.p. injections daily for 21 days. Age-matched, LC diet control mice were
maintained on the lab chow diet. Body weight and food intake were measured daily.
Teasaponin (96%, C57H90O26, MW=1200) was purchased from the Aladdin Chemistry
Co. Ltd, China. On day 18 of TS treatment, an intraperitoneal glucose tolerance test was
performed

(detailed in section 1.4.3). On day 21 of

TS1 treatment, an

intracerebroventricular cannula was implanted and central leptin sensitivity test was
performed (detailed in section 1.4.4). Figure 1.2 showed the flow chart experiment.
This part of chronic teasaponin treatment was included in chapter 4.

1.4.3 Intraperitoneal glucose tolerance test (IPGTT)
On day 18 of Rb1 (or Teasaponin) treatment, the mice were injected intraperitoneally
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with glucose at a dose of 0.5 g/kg after an overnight fasting. Blood samples were taken
from the tail vein, and blood glucose concentration determined using a glucometer
(Freestyle; Abbott Diabetes Care, Alameda, CA) at 0 (fasting), 30, 60 and 120 minutes
after glucose injection.

1.4.4 Central leptin sensitivity
Mice were anesthetized by isoflurane inhalation and placed in a stereotactic device. An
intracerebroventricular (icv) cannula was implanted into the right lateral brain ventricle
(0.25 mm posterior and 1.0 mm lateral relative to Bregma and 2.5 mm below the surface
of the skull) (Paxinos and Franklin, 2002). Five days after implantation the mice were
fasted for 6 hours, and either leptin (0.1 µg/3 µl) or saline (3 µl) was injected into the
lateral ventricle through the cannula. Food intake was measured for 1, 4, and 24 hours,
and body weight was measured 24 hours after the leptin or vehicle injection.
The accuracy of the cannula placement was histologically confirmed by the methylene
blue which was icv injected into the pre-experimental test animal before decapitated. The
cannula track of each animal was confirmed when sliced the brain. Figure 1.2 showed the
confirmation of correct placement of cannula.
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Figure 1.3 A pre-experimental histologically confirmation of the correct cannula placement at the
lateral ventricle and the correct location of injection were carried out using a Methylene Blue
injection (A). The accuracy of the cannula placement of the experimental animals was comfirmed
by examing the cannula track in the brain section of each animal. Sections were compared with the
corresponding section from the mice brain atlas (B).

1.4.5 Blood and Tissue collection
Following a further four day interval after examining central leptin sensitivity, mice were
fasted for 6 hours, administered an icv injection of either leptin (0.1 µg/3 µl) or saline (3
µl) and then euthanized 1 hour later for tissue collection. Blood, white adipose tissue,
liver and brain tissue were collected. The plasma was collected after centrifugation at
3000rpm for 15 minutes. Plasma and other tissues were stored at -80 °C for further
analyses.
Using a standard mouse brain atlas (Paxinos and Franklin, 2002), 500 µm frozen brain
sections were cut from Bregma -1.22 mm to -2.72 mm (for mediobasal hypothalamus),
Bregma 2.8-1.98 mm (for prefrontal cortex) using a cryostat at a temperature of -18 °C.
The mediobasal hypothalamus were dissected and then collected using a Stoelting Brain
Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting Co, USA) in an overlapping
pattern over the 3rd ventricle (White et al., 2009). The prefrontal cortex was also
dissected and collected by the stoelting brain punch.

1.4.6 Determination of plasma leptin, insulin, peptide YY (PYY) and
adiponectin
Plasma leptin, insulin and PYY were measured using the mouse metabolic magnetic bead
panel kit (Merck Millipore, MA), and adiponectin was assayed with the mouse single
plex adiponectin kit (Merck Millipore).

1.4.7 Histological analysis and morphometry
Epididymal fat was fixed in 10% buffered formaldehyde and then embedded in paraffin.
Tissue sections (5 μm) were cut and mounted onto polysine slides. The sections were
stained with hematoxylin and eosin and photographed at 100× magnification. Using the
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image analysis software Image J 1.46r (http://rsbweb.nih.gov/ij/download.html), two
fields per section and six sections per fat mass were analyzed to quantify the area and
number of adipocytes.

1.4.8 Western blot analysis
As described in our previous study (du Bois et al., 2012), tissue protein from liver (study
1, chapter 2), epididymal fat (study 1, chapter 2), mediobasal hypothalamus (study 1,
chapter 2) and prefrontal cortex (study 2, chapter 3; and study 3, chapter 4) was extracted
using NP-40 Lysis Buffer. The following antibodies were used: TNF-α (sc-8301), IL-1β
(sc-7884), IL-6 (sc-7920), pJAK2 (sc-21870), BDNF (sc-20981), TrkB (sc-), and pAkt
(sc-) from Santa Cruz Biotechnology (Dallas, TX); pTrkB 95 from Sigma-Aldrich (St.
Louis, MO, USA); and p-IκBα (#2859), p-IKK (#2697), p-STAT3 (#9145), SOCS3
(#2932), and p-FOXO1 (#9461), pGSK3β (#) from Cell Signaling Technology (Beverly,
MA). Bands corresponding to the proteins of interest were analyzed using the automatic
imaging analysis system Quantity One (Bio-Rad Laboratories, Hercules, CA). All
quantitative analyses were normalized to β-actin as described in our previous study (du
Bois et al., 2012).

1.4.9 Novel object recognition test
In animal study 3 (chapter 4), novel object recognition test was performed. This test is
based on the innate tendency of rodents to differentially explore novel objects over
familiar ones as previously described (Arqué et al., 2008), with minor modifications. In
brief, the experimental procedure consisted of habituation, training, and retention
sessions. On day 1, for habituation, mice were placed into an open-field box (55 × 55 cm
× 35 cm high) for 10 min with a 40 W light bulb in a sound proof room. On day 2, during
the training session, two identical objects (A) were placed at opposing corners of the box,
5 cm from the adjacent wall. Each mouse was then placed in the middle of the open-field
box and left to explore the objects for 10 min. Ninety minutes later, in the retention
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session, one familiar object (A) was replaced with one novel object (B). Each mouse was
placed in the middle of the open-field box, and left to explore for another 10min. The
exploration time for the familiar and the new objects was recorded. Memory was
operationally defined by the discrimination index for the novel object (DI) as the
proportion of time animals spent investigating the novel object minus the proportion
spent investigating the familiar one in the testing period in the retention session
[Discrimination Index = (Novel Object Exploration Time/Total Exploration Time) –
(Familiar Object Exploration Time/Total Exploration Time) × 100].

1.4.10 Primary prefrontal cortical neuronal cultures and treatment
Primary prefrontal cortical neuronal cultures was applied both in study 2 (Chapter 3) and
study 3 (Chapter 4). Mouse prefrontal cortical neuronal cultures were prepared from pups
at postnatal day 1-2 (C57Bl/6J mice, Perth, Western Australia) as described previously
(Hilgenberg and Smith, 2007). Dissociated cells were seeded at an approximate final
density of 1 x 105 cells/cm2 into a Poly-D-Lysine-coated 24-well plate (1.9 cm2/well) for
qRT-PCR measurement. For neuronal morphology measurement, the neurons were
cultured on Poly-D-Lysine-coated glass coverslips. In study 2 (Chapter 3), at 7 days in
vitro, Rb1 (40 µM, refer to (Liao et al., 2002)) was used to treat the cultures
simultaneously in the presence of palmitic acid (final concentration of 10 µM, P5585,
Sigma-Aldrich, St Louis, MO, USA). Palmitic acid was dissolved following the method
described previously (Ross et al., 2010). Four hours after palmitic acid and/or Rb1 preexposure, leptin (100 ng/mL, refer to (Valerio et al., 2006), Cat#: 450-31, Peprotech,
Rocky Hill, NJ, USA) or vehicle was added to the cultures for another 44 hours before
the cells were harvested.
In study 3 (Chapter 4), at 7 days in vitro, 20 µM or 40 µM teasaponin was used to treat
the cultures simultaneously in the presence of palmitic acid (10 µM). Four hours after
palmitic acid and/or TS pre-exposure, leptin (100 ng/mL, refer to (Valerio et al., 2006),
Cat#: 450-31, Peprotech, Rocky Hill, NJ, USA) or vehicle was added to the cultures for
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another 44 hours before the cells were harvested.

1.4.11 Quantitative real-time PCR (qPCR)
Total mediobasal hypothalamic RNA (study 1, Chapter 2), and total RNA from cultured
cells (study 2, Chapter 3; and study 3, Chapter 4) were extracted using the Aurum total
RNA mini kit (Bio-Rad Laboratories, Hercules, CA) and reverse-transcribed to firststrand complementary DNA with the high-capacity cDNA reverse transcription kit (AB
Applied Biosystems, Carlsbad, CA), according to the manufacturer’s instructions. qPCR
was performed in a 20 µl final reaction volume using SYBR green I master in a
Lightcycler 480 (F. Hoffmann-La Roche Ltd, Basel, Switzerland). Primers used are listed
in the table of each chapter. Amplification was carried out with 45 cycles of 95 °C for 10
seconds, 60 °C for 30 seconds and 72 °C for 30 seconds. The mRNA expression levels
for hypothalamic neuropeptides (study 1, Chapter 2), MAP2, PSD95, SYN and BDNF
(study 2, Chapter 3; and study 3, Chapter 4) were normalized to gamma actin, which
served as the internal control. Experiments were performed in triplicate. The level of
expression for each gene was calculated using the comparative threshold cycle value (Ct)
method, using the formula 2–ΔΔCt as described previously (Livak and Schmittgen, 2001;
Wilusz et al., 2008).

1.4.12 Immunofluorescence
Immunofluorescence and image analysis were applied in the study 2 (Chapter 3) and
study 3 (Chapter 4). For immunocytochemical staining, neurons were washed three times
in phosphate-buffered saline (PBS), and then fixed with 4% paraformaldehyde (SigmaAldrich, St Louis, MO, USA) for 30 min at room temperature. After rinsing with PBS,
the neurons were permeabilized with 0.3% Triton-X (Sigma-Aldrich) in PBS (i.e. PBST)
for 10 min, and blocked with 5% goat serum in PBST for 1 hour at room temperature.
Then anti-BDNF antibody, anti-microtubule-associated protein 2 (MAP2) antibody, anti-
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synaptophysin (SYN) antibody, and anti-post-synaptic density protein 95 (PSD 95)
antibody were applied overnight at 4°C. MAP2 was visualized by goat anti-mouse
secondary antibody conjugated with Alexa Fluor 594. BDNF, SYN, and PSD95 were
visualised with isotype-specific donkey anti-rabbit secondary antibody conjugated with
Alexa Fluor 488. The details of origin and concentration of antibodies were given in the
Table S1. A fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkochen, Germany)
with an attached digital camera was used to obtain MAP2 immunofluorescence images
for neuronal morphology analysis. A confocal microscope (Leica TCS SP5 Advanced
System, Wetzlar, Germany) equipped with a digital camera was used to obtain images for
immunoreactivity analysis of BDNF, PSD95, and SYN.

1.4.13 Neurite length and branching analysis
Neurite length and branching analysis were applied in the study 2 (Chapter 3) and study 3
(Chapter 4). The analysis was performed by the NeuriteQuant program (Dehmelt et al.,
2011), which is an open source toolkit ―NeuriteQuant V1.23‖ (http://www.ccb.tudortmund.de/groups/CB/bastiaens/dehmelt/Neurite Quant/) that to be installed as a plugin
for image J 1.40g (http://rsbweb.nih.gov/ij/download.html). The quantification of
neuronal morphology included: average neurite length, neurite length per cell, neurite
number per cell, branches per neurite, and branches per cell. Experiments were
independently performed three times, with each time repeated in triplicate (n=9). The
image analysis was based on these nine repeats.

1.4.14 Immunoreactivity analysis for BDNF, PSD95, and SYN
In study 2 (Chapter 3), software Image J 1.40g was used to quantify the
immunoreactivity of BDNF, PSD95, and SYN. Images were converted into a 16-bit scale
for analysis. The mean intensity of the fluorescence of these biomarkers in the cell body
was measured. Approximately 1-2 areas (around 10x10 μm2 per area) of the cell body per
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neuron were analyzed and 7-8 neurons per image were randomly selected. A range of 6-7
images per group from three independent experiments were analyzed. For PSD95 and
SYN, dendrite immunoreactivity was also analyzed. In each dendrite, 2-4 areas (around
10x10 μm2 per area) were measured, and 2-4 dendrites per neuron were analyzed.

1.4.15 Statistical analysis
Data were analyzed using the SPSS 19 statistical package (SPSS, Chicago, IL). The twotailed student’s t-test was used to compare food intake, adipose tissue histology and
weight, inflammatory markers in epididymal adipose tissue and liver, and hypothalamic
neuropeptides in study 1 (Chapter 2). One-way analysis of variance (ANOVA) was
followed by the post hoc Tukey–Kramer honestly significant difference (HSD) test was
used to analyze final body weight gain, body weight, energy intake, epididymal fat,
visceral fat, liver weight, glucose tolerance test, novel recognition test, plasma cytokines,
central inflammatory markers, central leptin sensitivity, as well as biomarkers of the in
vitro study and neuronal morphology data (study 1-3). A p<0.05 was regarded as
statistically significant, and p<0.10 were considered a trend. Values are expressed as
mean  SEM.
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CHAPTER TWO
Central Inflammation and Leptin Resistance Are Attenuated by
Ginsenoside Rb1 Treatment in Obese Mice Fed a High-Fat Diet

Reprinted from PLOS ONE, Open-access
Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092618
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Table S1 The primers used in qPCR for neuropeptide mRNA measurement
GENE

Forward primer

Reverse primer

NCBI reference

NPY

ATACTACTCCGC

GTGTCTCAGGGCTG

NM_023456.2

TCTGCGAC

GATCT

AGTTGTGTTCTG

CTGATGCCCTTCAG

CTGTTGGC

TGGAG

AgRP

POMC CCATAGATGTGT

γ-actin

Yizhen WU

CCAGCGAGAGGTC

NM_007427.2

NM_008895.3

GGAGCTGG

GAGTT

GCTAACAGAGA

CAGATGCATACAAG NM_009609.2

GAAGATGACG

GACAGC
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Table S2 Effects of acute Rb1 administration (14 mg/kg, ip, two days) on
body weight and food intake in obese mice after a high-fat diet feeding for 8
weeks
HF

HF + Rb1

BW before Rb1 treatment (g)

29.84 ± 0.49

29.59 ± 0.47

BW after Rb1 treatment (g)

30.12 ± 0.47

29.89 ± 0.43

FI of 24 hours after Rb1 treatment (g)

3.39 ± 0.16

3.44 ± 0.10

HF: high-fat diet-induced obese mice; Rb1: ginsenoside Rb1 treatment; BW:
body weight; FI: food intake. Data are presented as mean ± SEM.
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CHAPTER THREE
Ginsenoside Rb1 Improves Leptin Sensitivity in the Prefrontal Cortex in
Obese Mice

Reprinted from CNS Neuroscience & Therapeutics, Copyright (2018), with permission
from
Available at: http://onlinelibrary.wiley.com/doi/10.1111/cns.12776/abstract
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SUPPLEMENTARY DATA

Table S1. The antibodies used in this study
Peptide/protein

Name of Antibody

Manufacturer, catalog #

target

Species raised in

Dilution

monoclonal or polyclonal

used

Experiment

BDNF

BDNF (H-117)

Santa Cruz Biotechnology, sc-20981

Rabbit, Polyclonal

1:400

Western blot

p-JAK2

p-JAK2 (Tyr 1007/Tyr

Santa Cruz Biotechnology, sc-21870

Goat, Polyclonal

1:500

Western blot

Cell Signaling Technology, #9145

Rabbit, Monoclonal

1:2000

Western blot

1008)
p-STAT3

Phospho-Stat3 (Tyr705)
(D3A7) XP® Rabbit
mAb

BDNF

BDNF (H-117)

Santa Cruz Biotechnology, sc-20981

Rabbit, Polyclonal

1:100

Immunofluorescence

MAP2

Monoclonal Anti-MAP2

Sigma-Aldrich, #M4403

Mouse, Monoclonal

1:500

Immunofluorescence

Sigma-Aldrich, SAB4502906

Rabbit, Polyclonal

1:100

Immunofluorescence

Life Technologies, #51-6900

Rabbit, Polyclonal

1:500

Immunofluorescence

antibody
SYN

Anti-Synaptophysin
antibody

PSD95
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Table S2. Primers used in qPCR for mRNA measurement of synaptogenesis markers
Gene

Forward primer

Reverse primer

NCBI reference

BDNF

GGGTCACAGCGGCAGATAAA

GCCTTTGGATACCGGGACTT

NM_001285416.1

MAP2

ATGAAGGAAAGGCACCACAC

AATAGGTGCCCTGTGACCTG

NM_001039934.1

SYN

GAACAAGTACCGAGAGAACAACAA

GGTCAGTGGCCATCTTCACA

NM_009305.2

PSD95

GGTGACGACCCATCCATCTTTATC

CGGACATCCACTTCATTGACAAAC

NM_007864.3

γ-actin

GCTAACAGAGAGAAGATGACG

CAGATGCATACAAGGACAGC

NM_009609.2
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Table S3. Central leptin sensitivity and plasma level of leptin in experimental groups in response to icv leptin administration
LC

obese

obese + Rb1

Saline

Leptin

Saline

Leptin

Saline

Leptin

EI_1 hr. icv (Kcal)

2.3 ± 0.3

1.6 ± 0.4

1.0 ± 0.1

0.9 ± 0.1

0.5 ± 0.1b

0.4 ± 0.1c

EI_4 hrs. icv (Kcal)

5.2 ± 0.6

3.1 ± 0.4a

5.1 ± 0.6

4.9 ± 0.6

3.2 ± 0.4b

1.6 ± 0.2cd

Leptin (ng/mL)

0.6 ± 0.1

0.7 ± 0.1

16.9 ± 2.1a

17.3 ± 1.8

8.9 ± 1.1ab

8.3 ± 1.4c

Central leptin sensitivity

Central leptin sensitivity: Energy intake (EI) for 1, and 4 hours after icv leptin administration. LC: Lab-chow diet fed mice; obese:
obese mice induced by a high-fat diet; obese + Rb1: obese mice treated with Rb1 for 3 weeks.
a

p<0.05 vs. LC/saline group; bp<0.05 vs. obese/saline group; cp<0.05 vs. obese/leptin group; dp<0.05 vs. (obese + Rb1)/saline group.

Data are presented as mean ± SEM, n=6-8.
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Table S4. The levels of PSD95 and SYN mRNA expression in cultured prefrontal cortical neurons
Saline

Leptin

Control

PA

PA + Rb1

Control

PA

PA + Rb1

PSD

100.0 ± 9.7

105.6 ± 2.8

119.0 ± 3.3

139.1 ± 5.6a

103.6 ± 1.8b

130.7 ± 8.4c

SYN

100.0 ± 7.4

92.5 ± 6.8

107.3 ± 9.2

142.3 ± 9.7a

93.6 ± 8.7b

110.8 ± 6.5

PSD95: post-synaptic density protein 95; SYN: synaptophysin. PA: palmitic acid; Rb1: ginsenoside Rb1. Cultured primary
cortical neurons were treated on the 7th day of in vitro, with 10 μM PA or (10 μM PA + 40 μM Rb1) for 4 hours, then
supplemented with 100ng/mL leptin or vehicle for 44 hours more. After 48 hours' treatment, neurons were collected to
examine the mRNA expression levels of PSD95 and SYN. ap<0.05 vs. respective saline group; bp<0.05 vs. control/leptin;
c
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CHAPTER FOUR
Teasaponin improves hypothalamic and cortical leptin sensitivity in dietinduced obese male mice
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Teasaponin improves hypothalamic and cortical leptin sensitivity in
diet-induced obese male mice

Abstract:
Hypothalamic inflammation is involved in the pathogenesis of obesity and type 2 diabetes.
Obesity impairs cognition, and the leptin-induced increase of brain-derived neurotrophic factor
(BDNF) and neurogenesis. Tea consumption improves inflammation, cognition and increases
brain activation in the prefrontal cortex. This study examined whether teasaponin, an active
ingredient in tea, could improve central inflammation and leptin sensitivity in the
hypothalamus and prefrontal cortex of obese mice. Teasaponin (10mg/kg, intraperitoneal) for
21 days significantly decreased the food intake and body weight of high-fat (HF) diet-induced
obese mice. In the hypothalamus teasaponin decreased both pro-inflammatory cytokines and
inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also enhanced
the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in
the hypothalamus. Furthermore, teasaponin improved downstream leptin signaling (JAK2, and
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HF fed mice. Prefrontal
cortical neurons were cultured with teasaponin and palmitic acid (the most abundant dietary
saturated fatty acid) to examine their effects on BDNF and neurite outgrowth in response to
leptin. Palmitic acid decreased leptin’s effect on BDNF and neurite outgrowth in cultured
cortical neurons, which were reversed by teasaponin. Therefore, teasaponin supplementation
may be used to prevent obesity-associated neurodegeneration and improve cognitive function.

Keywords: Teasaponin, anti-inflammation, leptin sensitivity, diet-induced obesity
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4.1 Introduction
Obesity has reached epidemic proportions and is an important risk factor for the development
of type 2 diabetes, cardiovascular disease, and some forms of cancer. There is compelling
evidence that a large component of obesity-associated pathophysiology may stem from the
low-grade inflammation that occurs during obesity. This includes increased production of proinflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin 1 beta (IL1β) and interleukin 6 (IL-6), and activation of the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) inflammatory signaling pathway in adipose tissue, liver and the
hypothalamus of the brain (Osborn and Olefsky, 2012; Thaler et al., 2012).
Over nutrition induces inflammatory responses in peripheral metabolic tissues, including the
infiltration of pro-inflammatory cytokine secreting macrophages into the adipose tissue of
obese mice and humans (Osborn and Olefsky, 2012; Weisberg et al., 2003; Xu et al., 2003).
Recent research has identified a similar type of low-grade inflammation in the hypothalamus of
rodents (Thaler et al., 2012), where TNF-α, IL-6 and IκB kinase (IKK) mRNA expression are
increased within a week of starting a HFD. IKK along with inhibitor kappa B alpha (IκBα) are
components of the NF-κB signaling pathway, and commonly used to investigate inflammatory
signaling events. Hypothalamic inflammation results in central leptin resistance, hepatic insulin
resistance, a reduction in thermogenesis and cardiovascular disorders (Cai and Liu, 2012).
Therefore, blocking the peripheral and central inflammation induced by HFD has the potential
to treat obesity and metabolic syndrome. This could be achieved using novel therapies
incorporating effective natural agents, particularly agents with the dual properties of preventing
inflammation and controlling body weight.
Recent epidemiological studies have demonstrated that obesity increases the incidence of
cognitive decline in neurodegenerative diseases, such as vascular dementia (Hassing et al.,
2002; Singh-Manoux et al., 2012). Empirical evidence has linked high-fat diet (HF)-induced
obesity with impairments in learning and memory, including a decline in recognition memory
(Boitard et al., 2014b; Camer et al., 2015; Valladolid-Acebes et al., 2011). For example, HF for
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8 weeks impairs spatial learning in the eight-arm radial maze test, prior to metabolic alterations
linked to obesity developing and without significant changes in plasma glucose and insulin
levels (Valladolid-Acebes et al., 2011). HF treatment of juvenile rodents impairs long-term
spatial reference memory in the Morris water maze, without affecting acquisition or short-term
memory (Boitard et al., 2014b). Furthermore, in our previous study, recognition memory was
impaired in chronic HF fed mice as assessed by performing a novel object recognition test
(Camer et al., 2015). The prefrontal cortex plays an important role in higher cognitive function
(Cole et al., 2012a). Abnormal structure and dysfunction in the prefrontal cortex is associated
with cognitive decline and the pathogenesis of mood disorders (Fumagalli et al., 2003; Kanoski
et al., 2007b; Weickert et al., 2003). Furthermore, positron emission tomography has shown
that obese women have reduced activation in the prefrontal cortex in response to a meal than
lean women (Le et al., 2007). In preclinical animal studies, a high-fat diet reduces synaptic
plasticity in the prefrontal cortex (Val-Laillet et al., 2011b), which leads to learning and
memory impairments (Laroche et al., 2000a). Moreover, obese patients are leptin resistant and
have significantly higher levels of plasma leptin, which correlates with body fat mass
(Heymsfield et al., 1999). Our previous study showed that in rodents a high saturated fat diet
induces body weight gain followed by the development of obesity, which is accompanied by
peripheral and then brain leptin resistance (Lin et al., 2000b). Despite this, therapeutic
interventions targeting HF-induced cognitive impairment and central leptin resistance are
lacking.
The adipocyte-secreted hormone leptin has important effects on synaptogenesis and dendritic
morphology in the brain, which regulate energy homeostasis and facilitate learning and
memory (Bariohay et al., 2005b; Komori et al., 2006; Yamada et al., 2011). For example, in
vitro, leptin increases neurite outgrowth marker and synaptogenesis markers in mouse H19-7
HN neural cell lines, as well as stimulating hippocampal neurogenesis by increasing cell
proliferation and differentiation (Moon et al., 2013). Leptin replacement at physiological doses
for two years substantially increased the rate of development in most neurocognitive domains
in dividual with leptin gene mutation (Paz-Filho et al., 2008). Brain-derived neurotrophic factor
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(BDNF) plays an important role in synaptic plasticity and neurogenesis (Arancio and Chao,
2007; Noble et al., 2011), cognitive function (Grassi-Oliveira et al., 2008) and energy
metabolism (Yu et al., 2009) through the activation of its receptor, tropomyosin-related kinase
B (TrkB). BDNF is broadly expressed in the developing and adult mammalian brain,
particularly in the cerebral cortex, hippocampus, hypothalamus and brainstem (Noble et al.,
2011). Plasma BDNF levels are positively correlated to memory performance in female
patients with major depressive disorder (Grassi-Oliveira et al., 2008). Leptin administration
significantly increases hippocampal BDNF in control but not HF-induced obese mice
suggesting decreased central leptin sensitivity in obese mice (Yamada et al., 2011). Altogether,
this evidence suggests that leptin activation of BDNF in the central nervous system may be
involved in cognition, while brain leptin resistance could contribute to obesity related cognitive
decline.
From ancient times tea has been widely used as a healthy drink worldwide. Recent evidence
has emerged that tea can prevent obesity and abnormal glucose and lipid metabolism
(Beresniak et al., 2012b; Wolfram et al., 2006). The earliest use of tea for medicinal purposes
occurred in China, in roughly 2700 BC during the time of Emperor Shen Nung (Weisburger,
1997). During that time, it was believed to have health promoting properties, and was
frequently used as a fluid supply for patients with infectious diseases. Recently, the effect of
tea on inflammation has received increasing attention. Six cups of green tea daily for three to
eight weeks significantly reduced NF-κB signalling in men with prostate cancer prior to
undergoing prostatectomy, compared to the control group (Henning, 2012). Treatment of
genetically obese (ob/ob) mice with 1 % tea extract in diet for 6 weeks decreased hepatic TNFα protein, adipose TNF-α mRNA, and attenuated hepatic steatosis (Park et al., 2011). Increased
consumption of green tea was associated with a lower prevalence of cognitive impairment in a
cross-sectional study in 1003 Japanese (Kuriyama et al., 2006), and longitudinal analysis of
data from 1438 Chinese subjects (Ng et al., 2008). Phenolics and saponin are the two major
active components of tea extract. Phenolics in tea have been widely investigated in previous
studies, while teasaponin (TS), an important bioactive ingredient of tea extract, has received
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little attention. Teasaponin chemically, belongs to the oleanane-type pentacyclic triterpene
saponins, which are naturally derived inhibitors of NF-kB signaling and have antiinflammatory potential (Salminen et al., 2008a). Recently teasaponin (10mg/kg ip injection)
showed significant anti-inflammatory properties, by inhibiting paw oedema induced by
carrangeenan in rats (Sur et al., 2001). In the current study, we expanded these findings to
investigate the effect of teasaponin on recognition memory and leptin signaling in the
hypothalamus and prefrontal cortex of HF fed mice. We further investigated the effect of
teasaponin in cultured primary prefrontal cortical neurons in response to leptin and the
saturated fatty acid, palmitic acid.

4.2 Materials and Methods:
4.2.1 Animals
C57Bl/6J male mice (10 weeks old, body weight: 19.6 ± 1.4 g) were obtained from the Animal
Resources Centre (Perth, Western Australia), and housed in environmentally controlled
conditions (temperature 22 °C, 12 hour light/dark cycle). Lab chow (LC) served as the low-fat
control diet (5% fat, Vella Stock Feeds, Doonside, NSW, Australia) and was provided ad
libitum except where noted. Mice were acclimatised for one week prior to experimentation. All
procedures were approved by the Animal Ethics Committee, University of Wollongong, NSW,
Australia, and complied with the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes.

4.2.2 Intraperitoneal (ip) teasaponin treatment
Mice were placed on the HF (containing 60% fat by calories, Specialty Feeds, Western
Australia) for 16 weeks. The animals were then randomised into two groups, and administered
either teasaponin (10 mg/kg) or vehicle (saline) i.p. injections daily for 21 days. Age-matched,
LC diet control mice were maintained on the lab chow diet. Body weight and food intake were
measured daily. Teasaponin (96%, C57H90O26, MW=1200) was purchased from the Aladdin
Chemistry Co. Ltd, China.
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4.2.3 Intraperitoneal glucose tolerance test (IPGTT)
On day 18 of the teasaponin treatment, the mice were fasted overnight and given an ip
injection of glucose (0.5g/kg) as reported previously (Morton et al., 2013; Wu et al., 2014;
Yoshihara et al., 2010). Blood samples were taken from the tail vein and blood glucose
measured using a glucometer (Abbott Diabetes Care, Alameda, CA) at 0 (fasting), 30, 60 and
120 min after glucose administration.

4.2.4 Central leptin sensitivity test
After intraperitoneal teasaponin treatment for 21 days, mice were anaesthetised and placed in a
stereotactic device. A intracerebroventricular (icv) cannula was implanted into the right lateral
brain ventricle (0.25 mm posterior and 1.0 mm lateral relative to Bregma and 2.5 mm below
the surface of the skull) (Paxinos and Franklin, 2002). Five days after implantation, mice were
fasted for 6 hours and administered either leptin (0.1 µg/3 µl) or saline (3 µl) injected into the
lateral ventricle through the cannula. Food intake and body weight were measured 24 hours
after the leptin or vehicle injection to examine central leptin sensitivity.

4.2.5 Blood and tissue collection
Four days after the first central leptin sensitivity test, the mice received a second icv leptin or
saline injection and were sacrificed one hour later. Plasma and brain tissue were collected and
stored at -80 °C for further analyses as detailed below.

4.2.6 Measurement of plasma leptin and insulin
Plasma leptin and insulin were measured using the mouse metabolic magnetic bead panel kit
(Merck Millipore, MA, USA).

4.2.7 Western blot analysis
Protein expression in frozen prefrontal cortex (equivalent to the prelimbic cortex, PrL,
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dissected at the level of Bregma 2.8 mm to 1.98 mm) was determined using western blot as
described in our previous study (Yu et al., 2013). The following antibodies were used: TNF-α
(sc-8301), IL-1β (sc-7884) and IL-6 (sc-7920), BDNF, TrkB 145 and 95, pJAK2 and pAkt
(Santa Cruz, CA, USA); pTrkB 95 (Sigma-Aldrich, St Louis, MO, USA); and p-IKK
(Ser176/180) (#2697), p-IκBα (Ser32) (#2859), pSTAT3, pGSK3β and pFOXO1 (Cell
Signaling Technology, Beverly, MA, USA). Bands corresponding to the proteins of interest
were scanned and band density analysed using the Quantity One automatic imaging analysis
system (Bio-Rad Laboratories, Hercules, CA, USA). All quantitative analyses were normalised
to β-actin, based on our previous studies (Yu et al., 2013). Due to the small amount of tissue in
the prefrontal cortex, we used a previously described modified multi-strip western blot
(Kiyatkin and Aksamitiene, 2009; Yu et al., 2013).

4.2.8 Oral teasaponin treatment and the novel object recognition test
Mice were placed on a HFD for 8 weeks. The animals were then randomized into two groups,
continuation of HFD for 6 weeks, or HFD with 0.5% teasaponin for 6 weeks. Age-matched, LC
diet control mice were maintained on the lab chow diet. A novel object recognition test was
performed 5 weeks after commencing teasaponin treatment.
This test is based on the innate tendency of rodents to differentially explore novel objects over
familiar ones as previously described (Arqué et al., 2008), with minor modifications. In brief,
the experimental procedure consisted of habituation, training and retention sessions. On day 1,
for habituation, mice were placed into an open-field box (55×55cm × 35cm high) for 10
minutes with a 40 W light bulb in a sound proof room. On day 2, during the training session,
two identical objects (A) were placed at opposing corners of the box, 5cm from the adjacent
wall. Each mouse was then placed in the middle of the open-field box and left to explore the
objects for 10 minutes. Ninety minutes later, in the retention session, one familiar object (A)
was replaced with one novel object (B). Each mouse was placed in the middle of the open-field
box, and left to explore for another 10 minutes. The exploration time for the familiar and the
new objects was recorded. Memory was operationally defined by the discrimination index for
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the novel object (DI) as the proportion of time animals spent investigating the novel object
minus the proportion spent investigating the familiar one in the testing period in the retention
session [Discrimination Index = (Novel Object Exploration Time/Total Exploration Time)–
(Familiar Object Exploration Time/Total Exploration Time)×100].

4.2.9 Prefrontal cortical neuronal cultures and treatment
Prefrontal cortical neuronal cultures were prepared from postnatal day 1 mice as described
previously (Hilgenberg and Smith, 2007). Cells were plated at a final density of 5 × 105/cm2
into Poly-D-Lysine-coated 24-well culture plates for RT-PCR analysis. For neurogenesis
imaging, cortical neurons were cultured on Poly-D-Lysine-coated coverslips. At 7 days in
vitro, teasaponin (40µM) and/or palmitic acid (10 µM , P5585, Sigma-Aldrich) were added to
the cultures. The method for dissolving palmitic acid was as described by Ross et al (Ross et
al., 2010). Four hours after palmitic acid and/or teasaponin pre-exposure, leptin (100 ng/ml) or
vehicle was added to the cultures for another 44 hours before the cells were harvested.

4.2.10 Immunofluorescence and image analysis
For immunocytochemical staining, neurons were fixed with 4% paraformaldehyde and 4%
sucrose in Dulbecco's PBS for 20 min at room temperature. The samples were incubated with
PBS containing 0.2% Triton X-100 for 5 min, and blocked with 10% horse serum in PBS for 1
h at 37 °C. Then, the anti-BDNF antibody and anti-microtubule-associated protein 2 (MAP2)
and antibody were applied overnight at 4 °C. BDNF was visualized with isotype-specific
donkey anti-rabbit secondary antibody conjugated with Alexa Fluor 488; MAP2 was visualized
by goat anti-mouse IgG (H+L) secondary antibody conjugated to Alexa Fluor 594. A
fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkochen, Germany) with an attached
digital camera was used to obtain MAP2 immunofluorescence images for neuronal morphology
analysis. A confocal microscope (Leica TCS SP5 Advanced System, Wetzlar, Germany)
equipped with a digital camera was used to obtain images for immunofluorescence image of
BDNF.
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4.2.11 Neurite outgrowth and branching analysis.
The quantification of neuronal morphology included: average neurite length, neurite length per
cell, neurite number per cell, branches per neurite, and branches per cell. Experiments were
independently performed three times, with each time repeated in triplicate (n=9). The image
analysis was based on these nine repeats.

4.2.12 Statistical analysis
Data were analysed using the SPSS 19 statistical package (SPSS, Chicago, IL, USA). One-way
analysis of variance (ANOVA) and the post-hoc Tukey-Kramer honestly significant difference
(HSD) test were used to analyse the novel recognition test, body weight, and the glucose
tolerance test and leptin signaling of the LC, HF, and teasaponin treatment groups in response
to saline and leptin, as well as data from the cell culture experiments. A p value < 0.05 was
regarded as statistically significant. Values are expressed as meanSEM.

4.3 Results
4.3.1 Teasaponin reduced body weight and food intake in obese mice
When teasaponin was administrated via ip injection to HFD-induced obese mice it significantly
reduced body weight and food intake during the 21-day observation period (Fig. 1A and 1B).
The final body weight and average energy intake of the teasaponin group was also significantly
lower than the HF control group following treatment (final body weight: -11.05%, p = 0.004;
average energy intake: -24%, p < 0.001, Fig. 1A and 1C).
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Fig. 1 Chronic administration of teasaponin (TS, 10 mg/kg ip for 21 days) significantly decreased body
weight (A), daily food intake (B) and average energy intake (C) in obese mice (n=16) fed a high-fat (HF)
diet for 16 weeks. *p<0.05 vs. HF control group.

4.3.2 Teasaponin improved glucose tolerance, blood hormone profiles and discrimination
index
Glucose tolerance tests were performed to assess glucose homeostasis and insulin sensitivity in
HFD-induced obese mice treated with teasaponin. Blood glucose levels were lower at the 30
and 60 minute time points in the teasaponin treatment group compared to the HF controls
during the glucose tolerance test (Fig. 2A). The teasaponin treatment also decreased HOMA
(Fig. 2B), indicating that it reduced insulin resistance in the HFD-induced obese mice. HFDinduced hyperinsulinemia and hyperleptinemia were significantly reversed by teasaponin
treatment (Fig. 2C and 2D). Teasaponin attenuated HF-induced decline in discrimination index
reflecting recognition memory in the novel object recognition test in mice (Fig. 2E).
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Fig. 2 Chronic administration of teasaponin improved glucose tolerance (A) and HOMA (B), decreased
plasma insulin (C) and leptin (D) in obese mice (n=8) fed a high-fat (HF) diet for 16 weeks. *p<0.05 vs.
HF control group. The homeostasis model assessment of insulin sensitivity (HOMA) is calculated by
(fasting glucose [mmol/l] multiplied by fasting insulin [U/ml] divided by 22.5). (E) Teasaponin
attenuated HF-induced decline in discrimination index reflecting recognition memory in the novel object
recognition test in mice. Discrimination Index = (Novel Object Exploration Time / Total Exploration
Time) – (Familiar Object Exploration Time / Total Exploration Time) × 100. * p<0.05 vs. HF fed mice.
Data are presented as mean±SEM, n=10. LC: lab chow diet fed mice.

4.3.3 Teasaponin attenuated hypothalamic inflammation and improved central leptin
sensitivity and leptin signaling
Western blot analysis showed that in the mediobasal hypothalamus, a HFD elevated TNF-α,
IL-6, p-IKK and SOCS3 protein expression, which was significantly decreased by treatment
with teasaponin (Fig. 3A, 3B, 3D, and 3E). We also evaluated if leptin signaling in the CNS
improved in conjunction with the observed reduction in hypothalamic inflammation. Leptin
administered icv significantly decreased energy intake for 24 hours in LC diet fed mice (-40%,
p < 0.001; Fig 4A), but not in HFD fed animals (-18%, p = 0.421; Fig. 4B). While energy
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intake was significantly decreased in the teasaponin-treated mice receiving icv injections of
leptin compared with the icv injection of saline (-31%, p=0.023; Fig. 4B).
To clarify the mechanisms underlying the enhanced effect of leptin in the teasaponin-treated
mice, we measured p-STAT3 protein levels in the mediobasal hypothalamus after the chronic
treatment with teasaponin and leptin stimulation. Leptin administered icv significantly
increased p-STAT3 in LC diet fed mice (p < 0.001; Fig. 4C), while p-STAT3 did not
significantly increase in response to the leptin injection in control HFD-induced obese mice
(Fig. 4D). With the teasaponin treatment, the p-STAT3 level significantly increased after icv
leptin injection compared with icv saline (94%, p < 0.001) (Fig. 4D).

Fig. 3 Effect of chronic teasaponin treatment on the protein levels of inflammatory markers in the
mediobasal hypothalamus of obese mice fed a high-fat (HF) diet for 16 weeks. Chronic treatment of
teasaponin significantly decreased the level of the pro-inflammatory cytokines TNF-α (A), IL-6 (B) and
IL-1β (C), as well as the inflammatory signaling molecules p-IKK (D) and SOCS3 (E). n=6-8, *p<0.05
vs HF group.
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Fig. 4 Energy intake (EI) at 1, 4 and 24 hours after the icv injection of leptin or saline in low-fat (LC)
diet fed mice (n=7-8) (A), in obese mice fed a high-fat (HF) diet for 16 weeks with or without chronic
treatment of teasaponin (10 mg/kg ip daily for 21 days) (n=6-8) (B). STAT3 phosphorylation in the
mediobasal hypothalamus 1 hour after the icv injection of leptin or saline in LC diet fed mice (n=7-8)
(C) and obese mice fed a high-fat diet for 16 weeks with or without chronic treatment of teasaponin
(n=6-8) (D). *p<0.05 vs. icv injection of saline within the treatment group (LC, HF control, or HF with
TS treatment); #p<0.05 vs. HF group (vehicle) with an icv injection of leptin; +p<0.05 vs. HF group
(vehicle) with an icv injection of saline.

4.3.4 Teasaponin restored leptin-pJAK2-pSTAT3 signaling and improved leptinmediated BDNF expression in the prefrontal cortex of HF fed mice
Several molecules, including JAK2-STAT3 and Akt-FOXO1/GSK, have been established as
downstream mediators of leptin signaling in the hypothalamus (Benzler et al., 2013; Kim et al.,
2006; Morton et al., 2005). Here we examined the leptin signaling pathways JAK2-STAT3 and
Akt-FOXO1/GSK in the prefrontal cortex. An icv injection of leptin significantly increased
pJAK2 in the prefrontal cortex of LC mice (p<0.001), but not in HF fed mice (p>0.05, Fig.
5A). However, with teasaponin treatment, the leptin injection significantly increased pJAK2 in
HF fed mice compared to saline injection (p<0.05). There was a similar response in the
pSTAT3, downstream step of leptin/pJAK2 signaling in the LC, HF and teasaponin-treated HF
mice (Fig. 5B). Leptin significantly increased pSTAT3 by 42% in the prefrontal cortex of LC
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mice, while in HF fed mice pSTAT3 only increased by 16% after the leptin injection.
Following chronic teasaponin treatment, pSTAT3 increased by 46% in response to leptin
compared with the saline injection, suggesting that teasaponin improved leptin-pJAK2pSTAT3 signaling in HF fed mice. We also found that leptin significantly increased pAkt,
pGSK3β and pFOXO1 in the prefrontal cortex of LC but not in HF fed mice (p<0.05, Fig. 5CE). However, teasaponin treatment did not reverse impaired leptin-pAkt-pGSK3β/pFOXO1
signaling in HF fed mice.

Fig. 5 Effect of teasaponin treatment (TS, 10mg/kg, ip for 21 days) on leptin-pJAK2-pSTAT3 signaling
(A, B), pAkt-pGSK3β/pFOXO1 (C-E) and leptin-BDNF in the prefrontal cortex of high-fat diet (HF) fed
mice. *p<0.05 vs. saline in individual group. Data are presented as mean±SEM, n=8–9. LC: lab chow
diet fed mice.

4.3.4 Teasaponin improved leptin-mediated BDNF expression in the prefrontal cortex of
HF fed mice and cultured prefrontal cortical neuron
After icv leptin injection, the BDNF level in the prefrontal cortex was significantly increased in
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LC mice (p<0.05), but not in HF fed mice (Fig. 5F). Importantly, with chronic teasaponin
treatment, leptin increased BDNF levels compared to saline in the prefrontal cortex of HF fed
mice, suggesting that teasaponin treatment improved the leptin-induced increase in BDNF in
the prefrontal cortex. However, teasaponin treatment did not significantly alter basal BDNF
protein levels in HF mice (p>0.05).
In cultured prefrontal cortical neurons, immunostaining with ani-BDNF antibody showed a
granula distribution of BDNF in MAP2-positive neurons (Fig. 6A). Leptin treatment
significantly increased BDNF expression, evidencing by the strong immunoreactivity (Fig. 6B)
and substantial increase in mRNA expression (2.5-fold, p<0.05, Fig. 6C). However, following
palmitic acid pretreatment, leptin did not increase BDNF expression (Fig. 6B and 6C). This
suggests palmitic acid inhibits leptin stimulation of BDNF in prefrontal cortex neurons.
Importantly, teasaponin treatment significantly increased leptin-mediated BDNF mRNA
expression (p < 0.05, Fig. 6C) and immunoreactivity (Fig. 6B) in palmitic acid pre-treated
cortical neurons. Interestingly, teasaponin treatment also induced a significant increase in basal
BDNF expression (i.e. without leptin) in cortical neurons (Fig. 6B and 6C).

Fig. 6 Teasaponin improved leptin-mediated BDNF expression in the cultured prefrontal cortical
neuron. Immunocytochemistry images showing the typical BDNF-containing vesicles (indicated by
white arrowheads), taken by confocal microscope (Nikon) (A); Palmitic acid (PA) decreased leptininduced BDNF immunoreactivity (B) and mRNA expression (C) in cultured prefrontal cortical neurons,
which can be corrected by teasaponin (TS) (B and C); TS and leptin significantly increased BDNF
immunoreactivity in cortical neurons (B). Pretreatment with PA significantly inhibited leptin-induced
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BDNF (B and C); TS prevented PA from inhibiting the leptin-induced stimulation of BDNF. Data
expressed as mean ± SEM (n = 6, obtained from six independent culture wells). *p < 0.05. Leptin (100
ng/mL) was applied to the neuron cultures 4 hours after pre-treated with PA and/or TS, then lasted for
44-h exposure. Scale bar = 50 μm. TS: teasaponin; PA: palmitic acid.

4.3.5 Teasaponin promoted neurite outgrowth in response to leptin in cultured prefrontal
cortical neurons
We examined the effect of teasaponin on neurite outgrowth in cells treated with leptin and
palmitic acid (Fig. 7A and 7B). Morphological analyses showed that leptin significantly
increased the average neurite length (Fig. 7D) and total neurite length per cell (Fig. 7E) in
control cortical neurons, but not in palmitic acid treated neurons. Whereas with teasaponin pretreatment, leptin increased average neurite length (45%, p<0.05, Fig. 7D) and total neurite
length per cell (45%, p<0.05, Fig. 7E) compare to saline, suggesting teasaponin attenuated the
effect of palmitic acid on leptin-induced neurite length. However, the neurite number per cell in
cortical neurons was not affected by leptin, PA or teasaponin (Fig. 7F). Furthermore, leptin
treatment significantly increased neurite branching (branches per neurite: +59%, Fig. 7G,
branches per cell: +59%, Fig. 7H) compared with saline treatment in control neurons, but not in
palmitic acid treated neurons. With teasaponin pretreatment, leptin significantly increased
branches per neurite, but not branches per cell. The mRNA expression of MAP2, a neurite
marker, was also examined by RT-PCR. Teasaponin prevented palmitic acid from inhibiting
the leptin-induced stimulation of MAP2 mRNA (Fig. 7I).
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Fig. 7 Effect of teasaponin (TS) and palmitic acid (PA) on the leptin-induced neurite

outgrowth. A: represents fluorescence images obtained under Confocal Microscope (Nikon),
scale bar = 50 μm; B: an example of MAP2 immunofluorescence staining image (8 bit) used
for neuron morphology analysis, scale bar = 100 μm; C: an example of analysis tracing of
neuron morphology quantification by using NeuriteQuant toolkit. All parameters (D-H) used
were automatically analysed and calculated by the algorithm of NeuriteQuant in pixels, n=9; D:
Average neurite length; E: Neurite length per cell; F: Neurite number per cell; G: Branches per
neurite; H: Branches per cell; I: MAP2 mRNA expression measured by qRT-PCR (n=5-7).
*p<0.05 vs. saline in individual group. Data are presented as mean ± SEM. Leptin (100 ng/ml)
was applied to the neuron cultures 4 hours before 44 hour exposure to TS (20 or 40µM) or
palmitic acid (10 µM).

4.4 Discussion:
This study demonstrated that teasaponin treatment reduced obesity, hypothalamic
inflammation, and central leptin resistance in high-fat (HF) diet-induced obese mice. The anti-
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inflammatory effects of teasaponin were associated with an improved glycemic status in the
treated animals, evidenced by improved glucose tolerance, HOMA and fasting plasma insulin.
Furthermore, teasaponin decreased pro-inflammatory cytokines and inflammatory signaling in
the mediobasal hypothalamus, and enhanced the anorexigenic effect of central leptin
administration as demonstrated by the restoration of p-STAT3 signaling in the mediobasal
hypothalamus. Furthermore, chronic teasaponin treatment enhanced object recognition
memory, and improved leptin signaling and leptin-induced BDNF expression in the prefrontal
cortex of HF fed mice. Moreover, in cultured primary prefrontal cortical neurons, palmitic acid
impaired the effect of leptin on neurite growth, and teasaponin ameliorated these palmitic acid
induced effects.
Leptin promotes negative energy balance by signaling in the brain, and the hypothalamus is a
key region for the control of food intake by this hormone. This negative feedback loop
becomes disrupted in most obese individuals, resulting in a state known as central leptin
resistance. In this study we confirmed central leptin resistance in HFD induced obese mice. The
icv injection of leptin significantly decreased food intake in LC control mice, but not in HF
obese mice with hyperleptinemia. There are two mechanisms that explain central leptin
resistance, hyperleptinemia (Knight et al., 2010) and hypothalamic inflammation (Thaler et al.,
2012; Zhang et al., 2008). Firstly, it is reported that hyperleptinemia is required for the
development of leptin resistance in diet-induced obese mice (Knight et al., 2010). In the current
study, teasaponin significantly reduced body fat and dramatically ameliorated hyperleptinemia
induced by HFD-induced obesity. This may have reduced the overstimulation of the leptin
receptor and downstream signaling, thus improving central leptin sensitivity. Secondly, recent
studies have revealed that hypothalamic inflammation can mediate central leptin resistance in
HFD-induced obese rodents (Thaler et al., 2012; Zhang et al., 2008). Constitutive activation of
IKKβ in the hypothalamus of mice induced central leptin resistance and impaired leptin
signaling through p-STAT3 (Zhang et al., 2008). In contrast, a genetic or pharmacological
blockade of inflammatory signaling in the hypothalamus improved leptin sensitivity and
elevated p-STAT3 (Milanski et al., 2012; Zhang et al., 2008). In mice with an IKK knockout in
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hypothalamic AgRP neurons, the level of p-STAT3 was significantly increased in response to
icv administered leptin in animals fed a HFD (Zhang et al., 2008). In this study, teasaponin
decreased the expression of the hypothalamic pro-inflammatory cytokines and inflammatory
signaling molecules, such as TNF-α, IL-6, IL-1β and p-IKK. This may have contributed to the
improved leptin sensitivity and hypothalamic leptin signaling via p-STAT3 following the
teasaponin treatment in the diet-induced obese mice.
SOCS3 has been identified as a negative regulator of central leptin signaling. The
overexpression of SOCS-3 results in the inhibition of leptin signaling through JAK2/STAT3
(Bjørbæk et al., 1999). Negative feedback in response to excessive hormone stimulation is a
classical mechanism of hormone resistance. It is known that leptin stimulates the expression of
SOCS3, which directly inhibits leptin signaling in the hypothalamus (Bjørbæk et al., 1998).
Furthermore, overexpression of IKK in the hypothalamic neurons of mice increases SOCS3
mRNA expression and protein levels in the hypothalamus (Zhang et al., 2008). Therefore in the
current study, hyperleptinemia and hypothalamic inflammation in diet-induced obese mice may
activate a common negative regulator of leptin signaling, SOCS3, and contribute to central
leptin resistance. Upregulation of SOCS3 in POMC neurons leads to impairment of STAT3
signaling, with subsequent leptin resistance, obesity, and glucose intolerance (Reed et al.,
2010). In contrast, hypothalamic SOCS3-deficient rats exhibited enhanced leptin-induced
STAT3 activation, decreased body weight gain and improved metabolic parameters when
exposed to a high-fat diet (Liu et al., 2011b). In the present study, teasaponin significantly
decreased the level of SOCS3 in the hypothalamus of HF induced obese mice, suggesting that
SOCS3 is a potential target for teasaponin’s therapeutic intervention during obesity.
In the present study, central acute administration of leptin significantly increased its
downstream signaling molecule, pJAK2 and pSTAT3 in the prefrontal cortex of control mice.
In accordance with our results, another study demonstrated that systemic administration of
leptin activated STAT3 phosphorylation in cortical neurons, in a rat model of cerebral ischemia
(Amantea et al., 2011). We also have demonstrated that leptin activates pAkt, pFOXO1 and
pGSK3β, another leptin signaling pathway, in the prefrontal cortex of LC mice. In obesity
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plasma leptin is increased, which theoretically will prevent overeating and obesity. However,
this is not the case as leptin resistance is a pathology of obesity (Myers et al., 2008a).
Furthermore, obese subjects with hyperleptinemia have an increased prevalence of dementia
and other neurodegenerative disease (Carpenter et al., 2000; Carter et al., 2000; Lieb et al.,
2009b). Therefore, it is unlikely that high plasma leptin levels will appropriately activate
signaling pathways in the brain of obese individuals with leptin resistance. Indeed, our results
showed that, in HF fed obese mice, both the leptin-pJAK2-pSTAT3 and pAktpGSK3β/pFOXO1 signaling pathways were impaired in the prefrontal cortex. Importantly,
teasaponin treatment corrected alteration of the leptin-pJAK2-pSTAT3 signaling pathway in
the prefrontal cortex of HF fed mice. It has been reported that leptin replacement improves
cognition in leptin-deficient patients with a delay or decline of cognitive function (Paz-Filho et
al., 2008). The prefrontal cortex is important for cognitive control (Cole et al., 2012a), and HF
reduces synaptic plasticity in this region (Val-Laillet et al., 2011b) leading to learning and
memory impairments (Laroche et al., 2000a). Therefore, teasaponin may attenuate HF induced
impairments of leptin signaling in the prefrontal cortex, leading to improved recognition
memory.
In the prefrontal cortex, BDNF promotes neuronal plasticity and neurogenesis, which are
important for learning and memory (Kanoski et al., 2007b; Sakata et al., 2013a). HFD reduced
BDNF in the prefrontal cortex and impaired discrimination reversal learning in rats (Kanoski et
al., 2007b). A continuous icv infusion of antisense BDNF oligonucleotide resulted in an
impairment of spatial learning in rats, with a significant reduction of BDNF mRNA and protein
levels in the brain (Mizuno et al., 2003). In the clinic, it is reported that BDNF levels in plasma
are positively correlated to memory performance in patients with depression (Grassi-Oliveira et
al., 2008). Leptin administration has been shown to increase BDNF expression in the
hippocampus of mice, which can be blocked by pre-treatment with K252a, a blocker of the
BDNF receptor (Yamada et al., 2011). In this study, we observed that leptin stimulated BDNF
expression in the prefrontal cortex of control mice, but not in HF fed obese mice. In cultured
primary prefrontal cortical neurons, leptin increased neurite outgrowth, however, this effect
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was impaired by palmitic acid. Along with improving the leptin-pJAK2-pSTAT3 signaling
pathway, our results demonstrated a beneficial effect of teasaponin on the upregulation of
BDNF and neurite outgrowth by leptin. These results suggest that teasaponin-induced
activation of leptin signaling may have modulated BDNF expression, enhancing neurite
outgrowth in the prefrontal cortex and contributing to an improvement in recognition memory.
In summary, we have demonstrated that chronic teasaponin treatment significantly reduced
food intake and body weight in HFD-induced obese mice. Treatment with teasaponin
significantly ameliorated central inflammation by reducing pro-inflammatory cytokines and
inflammatory signaling molecules in the hypothalamus. Therefore, teasaponin has important
effects in improving glucose tolerance, central leptin sensitivity and hypothalamic leptin
signaling. These results identify a novel role for teasaponin as an anti-obesity and antiinflammatory agent. Furthermore, teasaponin improved recognition memory in the HF fed
mice. Through in vivo and in vitro studies we revealed that leptin activated leptin-pJAK2pSTAT3 and pAkt-pFOXO1/pGSK3β signalling, stimulated BDNF expression and neurite
outgrowth in the prefrontal cortex. However, these prefrontal cortex responses are impaired
when mice are fed a high-saturated fat diet, or neurons exposed directly to saturated fatty acid,
i.e. palmitic acid in vitro. Teasaponin treatment ameliorates alteration of leptin-pJAK2pSTAT3 and leptin-BDNF in the prefrontal cortex of HF fed mice. Treatment with teasaponin
also promoted leptin’s effect on neurite outgrowth in prefrontal cortical neurons. Since high fat
diet-induced obesity has been implicated in the progression of neurodegenerative diseases, such
as vascular dementia, teasaponin supplementation may have beneficial effects in attenuating
the progression of cognitive decline in obese patients and reducing the risk of
neurodegenerative diseases. The dose of teasaponin obtained by frequently drinking tea is
significantly lower than the doses used in this rodent study. In order to reach the effect
observed in this study, a supplemental delivery of teasaponin (oral or injection) would be
needed. Clinical trials would also be required to determine the optimum dose in humans.
Furthermore, the potential toxicity of long-term teasaponin exposure should be investigated
before teasaponin supplementation can be recommended.
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SUPPLEMENTARY DATA
Table S1. The antibodies used in this study
Peptide/protein

Name of Antibody

Manufacturer, catalog #

Species raised in monoclonal or

target

Dilution used

polyclonal

TNFα

TNFα Antibody (H-156)

Santa Cruz Biotechnology, sc-8301

rabbit, polyclonal

1:200

IL-6

IL-6 Antibody (H-183)

Santa Cruz Biotechnology, sc-7920

rabbit, polyclonal

1:200

IL-1β

IL-1β Antibody (H-153)

Santa Cruz Biotechnology, sc-7884

rabbit, polyclonal

1:200

pIKK

Phospho-IKKα/β (Ser176/180)

Cell Signaling Technology, #2687

1:1000

1:1000

(16A6) Rabbit mAb
SOCS3

SOCS3 (L210) Antibody

Cell Signaling Technology, #2932

BDNF

BDNF (H-117)

Santa Cruz Biotechnology, sc-20981

Rabbit, Polyclonal

1:400

TrkB 145 and 95

TrkB (H-181)

Santa Cruz Biotechnology, sc-8316

Rabbit, Polyclonal

1:500

pTrkB 95

Anti-phospho-Trk B (pTyr705)

Sigma-Aldrich, SAB4503786

Rabbit, Polyclonal

1:500

p-JAK2

p-JAK2 (Tyr 1007/Tyr 1008)

Santa Cruz Biotechnology, sc-21870

Goat, Polyclonal

1:500

p-STAT3

Phospho-Stat3 (Tyr705) (D3A7)

Cell Signaling Technology, #9145

Rabbit, Monoclonal

1:2000

XP® Rabbit mAb
pAkt

p-Akt1/2/3 (Ser 473)-R

Santa Cruz Biotechnology, sc-7985-R

Rabbit, Polyclonal

1:500

pGSK3β

Phospho-GSK-3β (Ser9)(5B3)

Cell Signaling Technology, #9323

Rabbit, Monoclonal

1:1000

Rabbit mAb
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Continued Table S1.
Peptide/protein

Name of Antibody

Manufacturer, catalog #

Species raised in monoclonal or

target

Dilution used

polyclonal

BDNF

BDNF Antibody (H-117)

Santa Cruz Biotechnology, sc-20981

Rabbit, Polyclonal

1:100

MAP2

Monoclonal Anti-MAP2 antibody

Sigma-Aldrich, #M4403

Mouse, Monoclonal

1:500
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Table S2. The primers used in qPCR for mRNA measurement of neurogenesis markers
GENE

Forward primer

Reverse primer

NCBI reference

BDNF

GGGTCACAGCGGCAGATAAA

GCCTTTGGATACCGGGACTT

NM_001285416.1

MAP2

ATGAAGGAAAGGCACCACAC

AATAGGTGCCCTGTGACCTG

NM_001039934.1

γ-actin

GCTAACAGAGAGAAGATGACG

CAGATGCATACAAGGACAGC

NM_009609.2
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CHAPTER FIVE
5.1 Overall Discussion and conclusions
The prevalence of obesity is a worldwide health problem, and it is an important risk factor for
the development of type 2 diabetes, cardiovascular disease, and certain cancer, as well as
depression, and neurodegenerative diseases. Obesity features as weight gain, fat deposition, and
energy homeostasis imbalance, obesity-associated central and peripheral inflammation, central
and peripheral leptin resistance, blunt leptin signaling, as well as obesity-associated
neurodegeneration and cognitive decline. Addressing these features issues will help to antiobesity, and reduced the risks of obesity-linked diseases. A chronic low-grade inflammatory
state during obesity is at the pathogenic core of obesity and type 2 diabetes. Therefore, it is
essential to develop novel therapeutic agents that have the ability of anti-obesity-associated
inflammation. Triterpene saponins, are groups of pant secondary metabolites with structurally
composed of a lipid soluble aglycone and a water soluble sugar residues. The amphiphilic
nature of the triterpene saponins suggests that they can intercalate into the cell membrane to
mediate the cellular events. Some plant-derived triterpene saponins are anti-inflammatory and
inhibit the NF-κB signaling pathway. In this study, ginsenoside Rb1, one of the triterpene
saponins, has been reported to have anti-inflammation and neuroprotective effect, has been
implicated to treat the central leptin resistance, obesity-associated inflammation, and glucose
intolerance, as well as to investigate whether it could improve leptin effects on BDNF,
synaptogenesis in the prefrontal cortical neurons of obese, using an in vivo and in vitro model.
Teasaponin, active ingredient derived from tea, has recently been showed anti-inflammation
properties. This study was to evaluate its effects on obesity, obesity-associated hypothalamic
inflammation, hypothalamic and cortical leptin sensitivity of the high-fat diet-induced obese
mice, as well as leptin-mediated BDNF expression and neurite outgrowth in the prefrontal
cortical neurons, using an in vivo and in vitro model.
► Central Inflammation and Leptin Resistance Are Attenuated by Ginsenoside Rb1
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Treatment in Obese Mice Fed a High-Fat Diet
A low-grade pro-inflammatory state is at the pathogenic core of obesity and type 2 diabetes. We
tested the hypothesis that the plant terpenoid compound ginsenoside Rb1 (Rb1), known to exert
anti-inflammatory effects, would ameliorate obesity, obesity-associated inflammation and
glucose intolerance in the high-fat diet-induced obese mouse model. Furthermore, we examined
the effect of Rb1 treatment on central leptin sensitivity and the leptin signaling pathway in the
hypothalamus. We found that intraperitoneal injections of Rb1 (14mg/kg, daily) for 21 days
significantly reduced body weight gain, fat mass accumulation, and improved glucose tolerance
in obese mice on a HFD compared to vehicle treatment. Importantly, Rb1 treatment also
reduced levels of pro-inflammatory cytokines (TNF-α, IL-6 and/or IL-1β) and NF-κB pathway
molecules (p-IKK and p-IκBα) in adipose tissue and liver. In the hypothalamus, Rb1 treatment
decreased the expression of inflammatory markers (IL-6, IL-1β and p-IKK) and negative
regulators of leptin signaling (SOCS3 and PTP1B). Furthermore, Rb1 treatment also restored
the anorexic effect of leptin in high-fat fed mice as well as leptin pSTAT3 signaling in the
hypothalamus. Ginsenoside Rb1 has potential for use as an anti-obesity therapeutic agent that
modulates obesity-induced inflammation and improves central leptin sensitivity in HFDinduced obesity.
► Ginsenoside Rb1 improves leptin sensitivity in the prefrontal cortex in obese mice
Obesity impairs leptin-induced regulation of brain-derived neurotrophic factor (BDNF)
expression and synaptogenesis, which has been considered to be associated with the incidence
of neuronal degenerative diseases, cognitive decline and depression. Ginsenoside Rb1 (Rb1), a
major bioactive component of ginseng, is known to have an anti-obesity effect and improve
cognition. This study examined whether Rb1 can improve central leptin effects on BDNF
expression and synaptogenesis in the prefrontal cortex during obesity using an in vivo and an in
vitro model. Rb1 chronic treatment improved central leptin sensitivity, leptin-JAK2-STAT3
signaling and leptin-induced regulation of BDNF expression in the prefrontal cortex of high-fat
diet induced obese mice. In cultured prefrontal cortical neurons, palmitic acid, the saturated fat,
impaired leptin-induced BDNF expression, reduced the immunoreactivity and mRNA
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expression of synaptic proteins, and impaired leptin-induced neurite outgrowth and
synaptogenesis. Importantly, Rb1 significantly prevented these pernicious effects induced by
palmitic acid. These results indicate that Rb1 reverses central leptin resistance and improves
leptin-BDNF-neurite outgrowth and synaptogenesis in the prefrontal cortical neurons. Thus,
Rb1 supplementation may be a beneficial avenue to treat obesity-associated neurodegenerative
disorders.
► Teasaponin improves hypothalamic and cortical leptin sensitivity in diet-induced obese
male mice
Hypothalamic inflammation is involved in the pathogenesis of obesity and type 2 diabetes.
Obesity impairs cognition, and the leptin-induced increase of brain-derived neurotrophic factor
(BDNF) and neurogenesis. Tea consumption improves inflammation, cognition and increases
brain activation in the prefrontal cortex. This study examined whether teasaponin, an active
ingredient in tea, could improve central inflammation and leptin sensitivity in the hypothalamus
and prefrontal cortex of obese mice. Teasaponin (10mg/kg, intraperitoneal) for 21 days
significantly decreased the food intake and body weight of high-fat (HF) diet-induced obese
mice. In the hypothalamus teasaponin decreased both pro-inflammatory cytokines and
inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also enhanced
the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in the
hypothalamus. Furthermore, teasaponin improved downstream leptin signaling (JAK2, and
STAT3), and leptin’s effect on BDNF, in the prefrontal cortex of HF fed mice. Prefrontal
cortical neurons were cultured with teasaponin and palmitic acid (the most abundant dietary
saturated fatty acid) to examine their effects on BDNF and neurite outgrowth in response to
leptin. Palmitic acid decreased leptin’s effect on BDNF and neurite outgrowth in cultured
cortical neurons, which were reversed by teasaponin. Therefore, teasaponin supplementation
may be used to prevent obesity-associated neurodegeneration and improve cognitive function.
This chapter will provide a general discussion and conclusions of the present PhD research
project undertaken. The main findings of this thesis are summarized in Table 5.1. Detailed
discussion of each study has been included in the discussion section at the end of chapter 2-4,
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while overall discussion of the findings is included in section 5.1.1. The proposed potential
treatment mechanisms of triterpene saponins are included in section 5.1.2 (Figure 5.1). The
conclusions of the thesis are presented in section 5.1.3. Based on the research outcomes of the
present project and the related existing knowledge, recommendations of future research are
included in section 5.1.4.
Table 5.1 The main finding of this project (Chapter 2-4)
-------Effects of Triterpene Saponins treatment
Parameters/ Reference
In vivo (DIO mice)
Food Intake (g)
Body Weight Gain
Final Body Weight
Fat Mass
Epididymal fat
Perirenal fat
Mesenteric fat
Inguinal fat
Adipocyte size
Liver Weight
Plasma profile
Leptin
Insulin
Adiponectin
PYY
Neuropeptides
POMC
AgRP
NPY
Glucose Tolerance
blood glucose at GTT
0 Minutes
30 Minutes
60 Minutes
120 Minutes
Peripheral Inflammation
Liver
IL-6
IL-1β
TNFα
pIKK
pIκBα
SOCS3

Yizhen Wu

Effect of Rb1
(Wu et al., 2018;
Wu et al., 2014)

Effect of Teasaponin
(Yu et al., 2015; Yu et al.,
2013)

↓
↓
NSD

↓
↓
↓

↓
↓
↓
↓
NSD

↓
↓
↓
↓
↓
↓

↓
NSD
↑
↑

↓
↓
↑
↑

↑
↓
NSD
Improved

↑
NSD
NSD
Improved

NSD
↓
↓
NSD

↓
↓
↓
↓

↓
NSD
↓
NSD
NSD
↓ (trend)

↓
NSD
↓
↓
↓
NSD
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Table 5.1 (Continued)

Parameters/ Reference

Effect of Rb1
(Wu et al., 2018; Wu et
al., 2014)

Effect of Teasaponin
(Yu et al., 2015; Yu et
al., 2013)

Epididymal fat
↓
NSD
IL-6
↓
↓
IL-1β
↓
↓
TNFα
↓
↓
pIKK
↓ (trend)
↓
pIκBα
Hypothalamic Inflammation
↓
↓
IL-6
↓
↓
IL-1β
NSD
↓
TNFα
↓
↓
pIKK
↓
↓
SOCS3
↓
PTP1B
Central leptin sensitivity
Acute treatment
↓
↓
4h EI
↓
↓
24h EI
↓
↓
24h BWG
Chronic treatment
↓
↓
4h EI
↓
↓
24h EI
↓
↓
24h BWG
Hypothalamic leptin signaling
↑
↑
pSTAT3
NSD
NSD
pFOXO1
↑
NSD
Prefrontal cortex BDNF
↑
↑
Prefrontal cortex Leptin-BDNF
Prefrontal cortex leptin signaling
↑
↑
pJAK2
↑
↑
pSTAT3
NSD
pAkt
NSD
pGSK3β
NSD
pFOXO1
In vitro (PA-treated primary cortical neurons)
Leptin-mediated BDNF
↑
↑
Immunoreactivity
↑
↑
mRNA
Leptin-mediated Neurite outgrowth
↑
↑
Branching
↑
↑
Length
↑
↑
MAP2 mRNA
Leptin-mediated synaptogenesis
↑ (dendrite and soma)
↑
PSD95 Immunoreactivity
↑
↑
PSD95 mRNA
↑ (in dendrite)
↑
SYN Immunoreactivity
NSD
NSD
SYN mRNA
Abbreviations: Rb1: ginsenoside Rb1; HFD: vs.: versus; high-fat diet; DIO: high-fat diet-induced obese;
NSD: no significant difference; PYY: peptide YY; POMC: Proopiomelanocortin; AgRp: Agouti generelated peptide; NPY: Neuropeptide Y; GTT: glucose tolerance test; BG: blood glucose; IL-6: Interleukin
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6; IL-1β: Interleukin-1β; TNFα: Tumor necrosis factor α; pIKK: ; pIκBα: ; SOCS3: Suppressor of
Cytokine Signaling 3; PTP1B: Protein Tyrosine Phosphatase 1B; EI: energy intake; BWG: body weight
gain; Ob: high-fat diet-induced obese mice; pJAK2: Phosphorylated Janus Kinase 2; pSTAT3:
Phosphorylated Signal Transducer and Activator of Transcription; pAkt: Phosphorylated Protein kinase
B; pGSK3β: Phosphorylated Glycogen synthase kinase-3; pFOXO1: Phosphorylated Forkhead box
protein O1; PA: palmitic acid; TS: teasaponin; BDNF: brain-derived neurotrophic factor; PSD-95: ; SYN:
synaptophysin.

5.1.1 Overall discussion of findings
In chapter 2, we reported Rb1 treatment decreased food intake, final body weight and reduced
fat deposition in the high-fat diet-induced obese mice. These results are consistent with a
previous report, which showed that Rb1 has an anti-obesity effect in rats and its suppression of
food intake is not due to malaise, as attested by a conditioned taste aversion test (Xiong et al.,
2010). Rb1 reduced fat deposition mainly attributed by the decreased in the adipocyte size and
the increased the number of small adipocytes and reduced the number of large adipocytes.
Importantly, this study also extends the mechanism of Rb1 in suppressing food intake. Rb1
treatment increased the anorexigenic hormone, peptide YY (PYY), in the blood and modulated
hypothalamic neuropeptides, specifically by increasing anorexigenic POMC and decreasing
orexigenic AgRP mRNA expression in the HFD-induced obese mice. Furthermore, this study
reported Rb1 decreased the protein level of pro-inflammatory cytokines (TNFα, IL-6 and IL-1β)
and inflammation signaling (pIKK) in the peripheral metabolic tissue, epididymal fat tissue and
liver. Since peripheral inflammatory responses induced by over nutrition and obesity has been
linked to decreases insulin sensitivity in target cells and contributed to glucose intolerance and
development of type 2 diabetes (Cai et al., 2005; Stanton et al., 2011a; Weisberg et al., 2003;
Xu et al., 2003), the anti-inflammation effect of Rb1 in the peripheral tissues of obese mice may
contributed to the improvement of glucose intolerance. Besides, Rb1 treatment elevated
circulation adiponectin, which has been indicated to ameliorate insulin resistance and reduced
fatty acids levels in rodent, may contribute to the improved glucose tolerance and reduced fat
accumulation we observed in the obese mice treated with this compound. Last, but not the least,
we observed that Rb1 ameliorated hyperleptinemia, reduced the hypothalamic inflammation,
PTP1B and SOCS3, improved central leptin signaling and restored central leptin sensitivity.
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Hypothalamic inflammation is considered a key pathology of obesity in rodents and humans
(Cai and Liu, 2012), leading to central leptin resistance through activation of the negative
regulators of leptin signaling, SOCS and PTP1B (Milanski et al., 2012; Zhang et al., 2008). Our
results demonstrate that Rb1 decreased the upregulation of SOCS3 and PTP1B in the
hypothalamus of HFD-induced obese mice. Therefore, the inhibition of SOCS3 and PTP1B and
attenuation of hypothalamic inflammation, contributes to the therapeutic effect of Rb1 on
central leptin resistance observed in our mouse model. The improvement of hyperleptinemia,
results from the reduction of fat mass, also contributes to the improvement of central leptin
sensitivity. Overall, this study demonstrated chronic Rb1 treatment inhibited inflammation in
the adipose tissue, liver, and the mediobasal hypothalamus of HFD-induced obese mice. Rb1
treatment also resulted in the improvement of glucose tolerance, central leptin sensitivity and
the hypothalamic leptin-pSTAT3 signaling. We also reported that Rb1 treatment increased
circulating anorexigenic hormone PYY and regulated the melanocortin POMC/AgRP
neuropeptides in the mediobasal hypothalamus, contributing to the negative energy balance.
Therefore, ginsenoside Rb1 is a potential anti-obesity therapeutic agent by modulating obesityassociated inflammation, improving central leptin sensitivity in the HFD-induced obesity.
In chapter 3, we expended these findings to investigate the effect of chronic Rb1 treatment on
leptin signaling and leptin-mediated BDNF regulation in the prefrontal cortex of high-saturated
fat diet–induced obese mice. We found that Rb1 upregulated BDNF protein expression and
corrected the impaired leptin-mediated BDNF regulation in the prefrontal cortex of obese mice.
Furthermore, Rb1 improved hyperleptinemia and restored leptin sensitivity on the regulation of
JAK2-STAT3 signaling in the prefrontal cortex of obese mice, by increasing these signal
protein phosphorylation. Moreover, we used an in vitro cultural primary cortical neuron model,
to evaluate the deleterious effect of saturated fatty acid, palmitic acid, on the leptin-mediated
BDNF regulation, and the leptin-mediated neurite outgrowth and synaptogenesis; as well as
investigate the treatment effect of Rb1 on the PA-pretreated cortical neurons. This study
indicated that, in the cultured primary prefrontal cortical neurons, palmitic acid impaired the
effect of leptin on BDNF, neurite outgrowth and synaptogenesis markers. Rb1 treatment
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improved the leptin-mediated BDNF expression, leptin-mediated neurite outgrowth (branching
and length) and synaptic proteins (SYN and PSD95) in palmitic acid pre-treated prefrontal
cortical neurons.
The present study demonstrated leptin elevates BDNF in the prefrontal cortex, as indicating by
protein expression level in the in vivo study and immunochemistry and mRNA in the in vitro
study. High-fat diet or palmitic acid altered the ability of leptin to elevates BDNF in the
prefrontal cortex, suggesting that a high-saturated fat diet can affect leptin function in the
prefrontal cortical neurons. These results are consistent with a previous report that demonstrated
the impairment of central leptin-regulated BDNF in obese mice, which is associated with
depressive behavior (Yamada et al., 2011). Moreover, mutation of the BDNF gene is associated
with increasing early-onset obesity and cognitive impairment in BDNF-haploinsufficient
patients (Gray et al., 2006). BDNF in the prefrontal cortex promotes neuronal plasticity and
neurogenesis, which are important for learning and memory (Kanoski et al., 2007a; Sakata et
al., 2013b). Thus, the impairment of leptin-regulated BDNF in the prefrontal cortex by saturated
fat may play an important role in central nervous system dysfunction in obese subjects. The
present study also demonstrated high-saturated diet substantially impaired leptin-JAK2-STAT3
signaling in the prefrontal cortex of obese mice, suggesting central leptin insensitivity in obese
mice. Central leptin insensitivity also exists in obese individuals. The prevalence of dementia
and other neurodegenerative diseases was higher in obese subjects with hyperleptinemia
(Carpenter et al., 2000; Carter et al., 2000; Lieb et al., 2009a), which suggests that high plasma
leptin levels unlikely activate signaling pathways in the brain of obese individuals. Therefore,
central leptin resistance is a pathology of obesity (Myers et al., 2008b). Leptin was shown to
regulate neurite outgrowth (branching and elongation) and synaptogenesis (PSD95 and SYN) in
the primary prefrontal cortical neurons in the present in vitro study. However, this ablility of
leptin was blunt by palmitic acid, indicating saturated fat impaired leptin-mediated neurite
outgrowth and synaptogenesis in cortical neurons. As prefrontal cortex is important for
cognitive control (Cole et al., 2012b), and high-fat diet reduces synaptic plasticity in this region
(Val-Laillet et al., 2011a) leading to learning and memory impairments (Laroche et al., 2000b).
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Therefore, taken all together, the impairment of leptin-mediated BDNF expression and leptinJAK2-STAT3 signaling by saturated fat in the prefrontal cortical neurons may attribute to the
impairment of leptin-mediated neurite outgrowth and synaptogenesis, and thus accelerate
neurodegeneration

and

cognitive

decline.

Importantly,

Rb1

treatment

improved

hyperleptinemia, improved leptin-mediated BDNF expression, as well as leptin-JAK2-STAT3
signaling, which may facilitated to the improvements of leptin-mediated PSD95 and leptinmediated SYN, and thus improved neurite outgrowth and synaptogenesis. These results suggest
that these effects of Rb1 may partly contribute to the improvement of cognitive function of
ginseng treatment in a clinic trial (Heo et al., 2011). Therefore, Rb1 may have beneficial effects
on obesity-associated neurodegenerative disorders.
In chapter 4, we demonstrated chronic teasaponin treatment reduced obesity, hypothalamic
inflammation, and central leptin resistance in high-fat diet-induced obese mice. Teasaponin
treatment enhanced object recognition memory, and improved hypothalamic and cortical leptinJAK2-STAT3 signaling and cortical leptin-induced BDNF expression of HFD fed obese mice,
as well as improved hyperleptinemia, hyperinsulinemia and glucose tolerance in obese mice.
Moreover, teasaponin treatment ameliorated the impairment on leptin-mediated BDNF, leptinmediated neurite outgrowth (branching and elongation) caused by saturated-fat, palmitic acid. It
is generally accepted that low-grade pro-inflammatory state is at the pathogenic core of obesity
and type 2 diabetes. Therefore, teasaponin is a potential anti-obesity therapeutic agent that
modulates obesity-induced inflammation and improves central leptin sensitivity in HFDinduced obesity. Previously, both clinical and animal studies have shown that tea improves
cognitive function (Kuriyama et al., 2006; Ng et al., 2008) and prevents impairments of learning
and memory (Morton et al., 2005). Furthermore, tea increases brain activity in the prefrontal
cortex of healthy volunteers as assessed by functional MRI methods (Borgwardt et al., 2012).
Therefore, the effect of teasaponin, an active gradient of tea extract, on enhancing object
recognition memory in obese mice, may contribute to the ability of tea to improve cognitive
function and memory, and increase brain activation in the prefrontal cortex, as described
previously (Borgwardt et al., 2012; Kuriyama et al., 2006; Ng et al., 2008). Cortical leptin
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resistance was observed in the obese mice, while teasaponin treatment restored leptin
sensitivity, illustrating by the improving of leptin-JAK2-STAT3 signaling in the prefrontal
cortex of teasaponin-treated obese mice. It has been reported that leptin replacement improves
cognition in leptin-deficient patients with a delay or decline of cognitive function (Paz-Filho et
al., 2008). Therefore, teasaponin may improve recognition memory via attenuate HFD induced
impairments of leptin signaling in the prefrontal cortex.
It is known that BDNF-mediated synaptic plasticity is usually coordinated by the synaptogenic
proteins, SYN and PSD-95 (Li and Keifer, 2012; Nelson et al., 2013; Robinet and Pellerin,
2011; Wolkowitz et al.). Consistent with this, along with increased BDNF levels, our findings
demonstrated that leptin stimulated SYN and PSD95 mRNA expression in vitro (Yu et al.,
2015). Furthermore, mRNA expression of the neurite outgrowth marker MAP2 increased in
response to leptin in cultured prefrontal cortical neurons. It is well established that leptin has
important effects on neurogenesis, synaptogenesis and dendritic morphology in the brain
(Valerio et al., 2006; Yamada et al., 2011). Overall, these results suggest that leptin may
promote neurogenesis and synaptic plasticity via increasing BDNF, SYN and PSD95 in cortical
neurons. It has been reported that a diet high in saturated fatty acids induces neuronal
degeneration and inactivates the leptin signaling molecule STAT3 in the hypothalamus of mice
(McNay et al., 2012). This is consistent with our in vitro results, suggesting that saturated fatty
acids also induce a leptin insensitivity effect on neurite outgrowth and synaptogenesis in the
prefrontal cortical neurons. We also found that teasaponin reversed this adverse effect of
palmitic acid on leptin-induced BDNF and neurite. It is known that the leptin signaling
molecules, JAK2 and STAT3, are distributed around the postsynaptic sites in the cerebral cortex
(Robinet and Pellerin, 2011). This suggests that teasaponin may modulate leptin signaling,
BDNF expression and post-synaptic function in the prefrontal cortex, leading to improved
recognition memory, suggesting the potential therapeutic effects on obesity-associated
neurodegenerative diseases and cognition decline.
Chronic treatment with triterpene saponins, i.e. ginsenoside Rb1 and teasaponin, in obese mice
is effective in the anti-obesity, anti-obesity-associated peripheral and central inflammation,
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improving hyperleptinemia and glucose intolerance, and correcting central leptin resistance, as
well as improving hypothalamic and cortical leptin sensitivity. Those results are consistent with
some of the clinic and animal data that ginseng or tea may act on anti-inflammation, antiobesity, and improve cognition (Borgwardt et al., 2012; Heo et al., 2011; Xiong et al., 2010).
Ginsenoside Rb1 and teasaponin are triterpene saponin, belonging to steroidal saponins, which
share structure features with steroid hormones (Attele et al., 1999a; Morikawa et al., 2006). Due
to the steroid-like structure and the amphiphilic nature (Abid Ali Khan et al., 2012; Attele et al.,
1999a; Morikawa et al., 2006), ginsenosides Rb1 or teasaponin can intercalate into the plasma
membrane replacing membrane cholesterol, which increases membrane fluidity and changes the
immediate environment of cell membrane proteins, such as the GABA receptor (Abid Ali Khan
et al., 2012; Attele et al., 1999a). Furthermore, ginsenoside may traverse cell membranes freely
and activate intracellular membrane receptors, such as steroid receptors, which may regulate the
transcription of target genes (Attele et al., 1999a). However, it remains to be determined if Rb1
or teasaponin directly interacts with leptin receptor.
Finally, both ginsenoside Rb1 and teasaponin ameliorated the impairment caused by palmitc
acid on leptin-mediated neurite outgrowth and synaptogenesis in the primary cortical neurons.
Besides, oral teasaponin has been demonstrated to improve recognitive memory. Taken all
together, triterpene saponins (both ginsenoside Rb1 and teasaponin) have neuroprotective
effects that can be potential therapeutic agents on treating obesity-associated neurodegenerative
diseases.

5.1.2 Proposed Mechanisms of Triterpene saponins in Overall discussion of findings
Figure5.1 proposed the possible mechanisms of triterpene saponins (ginsenoside Rb1 and
teasaponin) on treating obesity, obesity-associated inflammation and leptin resistance, as well as
mechanisms of triterpene saponins (ginsenoside Rb1 or Teasaponin) on treating leptin
insensitivity in the prefrontal cortex impaired by high-fat diet or high saturated fat, palmitic
acid.
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1. Long term maintaining mice on a high-fat diet containing saturated fat enlarges the
adipocytes size and increases the proportion of large adipocytes in adipose tissue, causing fat
deposition; as well as increases food intake and body weight gain, and thus becomes obese. Fat
deposition increases the circulating leptin, contributes to the hyperleptinemia. During the
obesity development, central inflammation plays a pathologic role, that increasing negative
leptin regulator PTP1B and SOCS3 protein expression, and thus contributes to central leptin
resistance and the impairment of leptin signaling (including pSTAT3, and pFOXO1) in the
hypothalamus. Hyperinsulinemia exists in the obese mice. High-fat diet-induced obesity results
in peripheral inflammation in liver and adipose tissue, which together with hyperinsulinemia,
causes glucose intolerance. Peripheral inflammation, together with hyperleptinemia, also
contributes to the peripheral leptin resistance. Importantly, chronic treatment the obese mice
with ginsenoside Rb1 or teasaponin for three weeks, reduced food intake via increasing
circulating anorexigenic hormone PYY expression and upregulation of anorexigenic
neuropeptide POMC, as well as downregulation of orexigenic neuropeptide AgRP in
mediobasal hypothalamus. Rb1 treatment also reduced body weight gain and adipocyte size and
fat deposition, thus ameliorated obesity. Rb1 or teasaponin treatment reduced central
inflammation and negative regulators (PTP1B and/ or SOCS3) of leptin signaling, then
improved central leptin sensitivity. Rb1 treatment reduced peripheral inflammation in liver and
adipose tissue, contributing to the improvement of glucose intolerance and peripheral leptin
resistance.
2. High-fat diet-induced obese mice developed hyperleptinemia and central leptin resistance in
prefrontal cortex, which induced the downregulation of leptin-mediated BDNF protein
expression. As BDNF is essential for the neurite outgrowth and synaptogenesis, therefore, highfat diet or high saturated fat caused the downregulation of leptin-mediated neurite outgrowth
(MAP2) and synaptogenesis (PSD95 and SYN). Importantly, treatment with ginsenoside Rb1 or
Teasaponin, ameliorated the impairment caused by high-fat diet or high saturated fat, improved
leptin-pSTAT3 signaling, leptin-mediated BDNF, leptin-mediated neurite outgrowth (branching
and elongation) and synaptogenesis in the prefrontal cortex. Thus, treatment with triterpene
Yizhen Wu

100

saponins (ginsenoside Rb1 or Teasaponin) will potentially improve cognition and
neurodegenerative disorders.

Figure 5.1 Proposed mechanism of ginsenoside Rb1 treatment on obesity, obesity associated
inflammation and leptin resistance; and proposed mechanism Rb1 or teasaponin improves
cortical leptin sensitivity and synaptogensis in high-fat diet-induced obese mice.
Abbreviation: HFD: high-fat diet; Rb1: ginsenoside Rb1; FI: food intake; BWG: body weight gain; PYY:
peptide YY; POMC: Proopiomelanocortin; AgRP: Agouti gene-related peptide; PTP1B: Protein Tyrosine
Phosphatase 1B; SOCS3: Suppressor of Cytokine Signaling 3; pSTAT3: Phosphorylated Signal
Transducer and Activator of Transcription; pFOXO1: Phosphorylated Forkhead box protein O1; BDNF:
brain-derived neurotrophic factor; MAP2: microtubule-associated protein 2; SYN: synaptophysin;
PSD95: Protein Tyrosine Phosphatase 1B.

5.1.3 Conclusions
The results of present PhD thesis have been demonstrated the treatment effects of triterpene
saponins (ginsenoside Rb1 and Teasaponin) on the high-fat diet-induced obese mice. All results
are summarized in table 5.1, and proposed mechanisms are showed in Figure 5.1.
In conclusions, food intake, body weight gain, fat deposition, hyperleptinemia, as well as
glucose intolerance in the high-fat diet-induced obesity can be improved by chronic ginsenoside
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Rb1 treatment. Obesity-associated peripheral inflammation and hypothalamic inflammation can
be reduced by Rb1 treatment, indicating by the decrease expression of TNFα, IL-6, IL-1β and
pIKK. Rb1 treatment also decreased the protein expression of SOCS3 and PTP1B, the negative
regulators of leptin signaling. The reduced central inflammation and downregulation of SOCS3
and PTP1B by Rb1 treatment, contributed to the improvement of central leptin resistance and
restore leptin signaling in the mediobasal hypothalamus of obese mice treated with Rb1.
Reduced peripheral inflammation contributed to the improvement of glucose intolerance.
Besides, the increased expression of circulating PYY, and hypothalamic POMC upregulation
and AgRP downregulation extend the mechanism on suppressing food intake by Rb1. Obesity
impaired prefrontal cortex and induced leptin insensitivity in the cortical neuron in vivo and in
vitro. Treated by the triterpene saponins, ginsenoside Rb1, leptin sensitivity in the prefrontal
cortex of obese was improved, evidencing by the improvement of cortical leptin-JAK2-STAT3
signaling, leptin-mediated BDNF expression, leptin-mediated neurite outgrowth (MAP2 mRNA,
branching and neurite length) and synaptogenesis (PSD95 immunoreacitvity and mRNA).
Teasaponin, the second triterpene saponin we tested, has been demonstrated that reducing food
intake, body weight, improving hyperleptinemia and hyperinsulinemia, as well as improving
glucose intolerance in the high-fat diet-induced obese mice. Chronic teasaponin treatment also
decreased hypothalamic inflammation, improved central leptin resistance, and restored
hypothalamic and prefrontal cortical leptin sensitivity via leptin-STAT3 signaling in obese mice.
Using an in vitro prefrontal cortical model, we demonstrated that teasaponin treatment reversed
the impairment by palmitic acid on the leptin-mediated BDNF expression and neurite outgrowth
(branching and elongation).
Taken all together, triterpene saponins, including ginsenoside Rb1 and teasaponin, have
beneficial effects on anti-obesity, on treating obesity-associated leptin resistance, obesityassociated inflammation, and obesity-associated neurodegenerative disorders.

5.1.4 Recommendation for Future Research
Based on the findings of the current series of studies, recommendation for future research are
Yizhen Wu

102

listed as follows:
1. In the current study treatment of obese mice with Rb1 restored leptin induced activation of
STAT3 phosphorylation, but not phosphorylation of FOXO1 in the mediobasal hypothalamus.
Therefore, in the hypothalamus, Rb1 acted on the STAT3 signaling pathways rather than the
FOXO1 pathway to restore leptin signaling and sensitivity. The precise mechanisms need
further examination.
2. In the current study, we demonstrated Rb1 elevated circulating PYY in the treated obese
mice. PYY is a gut-brain anorexigenic hormone that promotes negative energy balance by
reducing appetite (Boey et al., 2008). The increased plasma PYY in Rb1 treated obese mice may
have contributed to the negative energy balance, lower body weight gain and fat accumulations
in these animals. The mechanism by which Rb1 treatment increased circulating PYY levels
requires to be further determined.
3. This study demonstrated that Rb1 increased leptin sensitivity in the prefrontal cortex of obese
mice, and in prefrontal cortical neurons treated with palmitic acid, as well as reversed the
alterations of leptin downstream signaling molecules (pJAK2, STAT3, BDNF, and PSD95).
However, further study needs to be carried out to determine if Rb1 directly interacts with the
leptin receptor.
4. This study illustrated that Rb1 treatment ameliorated alteration of leptin-JAK2-STAT3 and
leptin-BDNF in the prefrontal cortex of obese mice and improves hyperleptinemia. Rb1
treatment also promoted leptin’s effect on neurite branching and elongation, and synaptogenesis
in prefrontal cortical neurons. As high-fat diet-induced obesity has been implicated in the
progression of neurodegenerative diseases, such as vascular dementia. Rb1treatent may have
therapeutic effects in attenuating the progression of cognitive declines in obese patients and
reducing the risk of neurodegenerative diseases. This will be the next work to further validate
using obese mice model.
5. This study presented teasaponin improved leptin sensitivity in the prefrontal cortex of obese
mice and primary cortical neurons treated with palmitic acid, and reversed the alterations of
leptin downstream signaling. According to the amphiphilic nature and able to intercalated into
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the plasma membrane, replacing membrane cholesterol and increasing membrane fluidity, and
thus this molecule could change the immediate environment of cell membrane proteins.
However, it is required to further investigate if teasaponin directly interacts with the leptin
receptor.
6. This study present oral teasaponin improved the recognition memory in treated obese mice.
Since high fat diet-induced obesity has been implicated in the progression of neurodegenerative
diseases, such as vascular dementia, teasaponin supplementation may have beneficial effects in
attenuating the progression of cognitive decline in obese patients and reducing the risk of
neurodegenerative diseases. However, the eventual toxicicity of long-lasting exposition to
elevated concentrations of teasaponin should be examined before teasaponin supplementation to
be recommended.
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